[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 192
1. Baumert H, Ballaro A, Dugardin F, Kaisary AV: Laparoscopic versus open simple prostatectomy: a comparative study. J Urol; 2006 May;175(5):1691-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Laparoscopic simple prostatectomy has recently been developed to remove large prostatic adenomas causing bladder outflow obstruction.
  • A Millin and a transvesical-prostatic technique were used in the laparoscopic group and a transvesical technique was used in the open group.
  • RESULTS: There was no significant difference in prostatic size, patient age or body mass index between the 2 groups.
  • In the laparoscopic group the mean International Prostate Symptom score +/- SD improved from 22.4 +/- 6.9 to 5.7 +/- 3.6 and the urinary flow rate improved from 8.1 +/- 2.5 to 24.6 +/- 12.1 ml per minute (each p <0.001).
  • Further studies are indicated to determine whether this technique should be considered the treatment of choice for prostatic adenomas too large for safe endoscopic resection.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600732.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Desai MM, Fareed K, Berger AK, Astigueta JC, Irwin BH, Aron M, Ulchaker J, Sotelo R: Single-port transvesical enucleation of the prostate: a clinical report of 34 cases. BJU Int; 2010 May;105(9):1296-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-port transvesical enucleation of the prostate: a clinical report of 34 cases.
  • OBJECTIVE: To present our experience with single-port transvesical enucleation of the prostate (STEP) in 34 patients with large-volume benign prostatic hyperplasia (BPH).
  • The mean prostate volume estimated by transrectal ultrasonography was 102.5 mL and the mean baseline prostate-specific antigen level was 6.7 ng/mL.
  • After establishing pneumovesicum, the prostate adenoma was enucleated transvesically using standard laparoscopic instruments, and the adenoma was extracted in pieces through the port.
  • Digital assistance expedited enucleation of the apical adenoma in 19 (55%) cases.
  • Under pneumovesicum using laparoscopic visualization, the entire adenoma can be effectively enucleated and expeditiously extracted through the novel single port.
  • [MeSH-major] Laparoscopy. Laser Therapy / methods. Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Robotics

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346053.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Modi P, Helfand BT, McVary KT: Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen. Curr Urol Rep; 2010 Jul;11(4):224-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen.
  • Prostate-specific antigen (PSA) is the most widely used marker for prostate cancer (CaP) screening and monitoring benign prostatic hyperplasia (BPH) progression.
  • However, lack of an established abnormal threshold and the presence of other benign processes confound the interpretation of PSA levels.
  • For example, the commonly used 5 alpha reductase inhibitor (5ARI) medications directly affect PSA levels by decreasing prostate volume.
  • The amount of time and potentially even the 5ARI formulary a patient is administered has been implicated to directly impact the degree of reduction in PSA (a proxy for prostate volume).
  • In addition, each of the currently available surgical procedures for BPH appears to remove varying amounts of prostatic adenoma.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / therapy


Advertisement
4. Kravchick S, Cytron S, Stepnov E, Ben-Dor D, Kravchenko Y, Peled R: 7 to 10 years' follow-up of 573 patients with elevated prostate-specific antigen (&gt;4 ng/mL) or/and suspected rectal examination: biopsies protocol and follow-up guides. J Endourol; 2009 Jun;23(6):1007-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 7 to 10 years' follow-up of 573 patients with elevated prostate-specific antigen (>4 ng/mL) or/and suspected rectal examination: biopsies protocol and follow-up guides.
  • PATIENTS AND METHODS: We included in this study 600 consecutive patients with suspicious findings on a per-rectum examination and/or an elevated prostate-specific antigen (PSA) (>4 ng/mL) level.
  • In all patients, we took from 8 to 16 biopsy samples, according to the prostate volume, from the lateral aspects.
  • TRUS-biopsy detected prostate cancer (PCa) in 257 patients (44.85% overall detection rate).
  • Prostate volumes were significantly smaller (52.9 +/- 22.4 cc vs 58.9 +/- 23.8 cc, P < 0.002) and the PSA/adenoma/prostate volumes ratio (ad-pro) ratio was higher (18.3 +/- 9 vs 13.96, P < 0/001) in the patients with PCa.
  • Patients with PCa underwent fewer biopsy procedures and biopsy sessions than patients without a diagnosis of PCa (14.9 +/- 8.9 vs 20.4 +/- 12, P < 0.001;1.3 +/- 0.6 vs 1.7 +/- 0.9, P < 0.001).
  • Numbers of biopsy procedures and PSA/ad-pro ratio were the strongest predictive factors for PCa detection (P < 0.001).
  • CONCLUSIONS: In patients with a prostate volume >or=53 cc and PSA/ad-pro ratio >or=18, the optimal biopsy cores should be >or=15.

  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19456240.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


5. Chepurov AK, Bulantsev DIu: [Comparative assessment of anatomo-functional features of the vesico-urethral segment and urinary bladder before and after surgical interventions for prostatic adenoma]. Urologiia; 2007 Jan-Feb;(1):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative assessment of anatomo-functional features of the vesico-urethral segment and urinary bladder before and after surgical interventions for prostatic adenoma].
  • [MeSH-major] Prostatic Hyperplasia / surgery. Urethra / pathology. Urethra / physiopathology. Urinary Bladder / pathology. Urinary Bladder / physiopathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472005.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 71
  •  go-up   go-down


6. Yun HK, Kwon JB, Cho SR, Kim JS: Early Experience with Laparoscopic Retropubic Simple Prostatectomy in Patients with Voluminous Benign Prostatic Hyperplasia (BPH). Korean J Urol; 2010 May;51(5):323-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early Experience with Laparoscopic Retropubic Simple Prostatectomy in Patients with Voluminous Benign Prostatic Hyperplasia (BPH).
  • PURPOSE: Laparoscopic simple prostatectomy was recently developed to treat voluminous benign prostatic hyperplasia (BPH).
  • The subjects were limited to the patients who satisfied the following conditions: prostate volume was at least 75 g, acute urinary retention repeatedly occurred or maximal flow rate (Qmax) was at most 10 ml/s, and International Prostate Symptom Score (IPSS) was at least 12.
  • Mean preoperative prostate-specific antigen and prostate volume were 6.1 ng/ml and 109.3 cc, respectively.
  • The resected adenoma weighed on average 72.4 g.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Korean J Urol. 2010 Feb;51(2):115-21 [20414424.001]
  • [Cites] World J Urol. 2009 Jun;27(3):385-7 [19082604.001]
  • [Cites] Eur Urol. 1999;36 Suppl 3:28-32 [10559628.001]
  • [Cites] J Urol. 2001 Feb;165(2):459-62 [11176396.001]
  • [Cites] Urology. 2001 Nov;58(5):642-50 [11711329.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 2):999-1003; discussion 1004 [11908420.001]
  • [Cites] J Urol. 2002 Jun;167(6):2528-9 [11992078.001]
  • [Cites] Urology. 2002 Oct;60(4):623-7 [12385922.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):530-47 [12853821.001]
  • [Cites] Eur Urol. 2004 Jan;45(1):103-9; discussion 109 [14667525.001]
  • [Cites] Urology. 2004 Apr;63(4):778-9 [15072905.001]
  • [Cites] Eur Urol. 2004 Nov;46(5):547-54 [15474261.001]
  • [Cites] BJU Int. 2005 Mar;95(4):676-8 [15705103.001]
  • [Cites] J Urol. 2005 Mar;173(3):757-60 [15711263.001]
  • [Cites] Eur Urol. 2006 Jan;49(1):127-31; discussion 131-2 [16314034.001]
  • [Cites] J Urol. 2006 May;175(5):1691-4 [16600732.001]
  • [Cites] Eur Urol. 2008 Jan;53(1):160-6 [17869409.001]
  • [Cites] Eur Urol. 2008 Aug;54(2):427-37 [18069117.001]
  • [Cites] Eur Urol. 1999;36 Suppl 3:14-20 [10559626.001]
  • (PMID = 20495695.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2873886
  • [Keywords] NOTNLM ; Laparoscopy / Prostate / Prostatectomy / Prostatic hyperplasia
  •  go-up   go-down


7. Martella O, Galatioto GP, Pace G, Vicentini C: PSA supernormalisation: a surrogate of complete adenoma removal in men with benign prostatic hyperplasia. Arch Ital Urol Androl; 2010 Dec;82(4):139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PSA supernormalisation: a surrogate of complete adenoma removal in men with benign prostatic hyperplasia.
  • It is known that serum prostate-specific antigen levels (PSA) decrease gradually following surgery for benign prostatic hyperplasia (BPH), but there is not an established cut-off value for normal PSA after relief of obstruction.
  • We evaluated the impact of prostatic adenoma enucleation on PSA levels in 110 patients who underwent transvesical suprapubic adenomectomy for symptomatic BPH.
  • We examined PSA levels before and after open surgery and weight of the prostatic adenoma as measured by the pathologist.
  • In patients with suspected abnormality on digital rectal examination or PSA > 4.0 ng/mL systematic multisite biopsies were performed preoperatively to rule out prostate cancer.
  • The mean weight of enucleated adenoma was 87 gr (range 50-201).
  • PSA supernormalisation represents an objective measure of complete adenoma removal.


8. Martov AG, Ergakov DV: [The experience in dutasteride use before transurethral prostatic resection for large adenoma]. Urologiia; 2008 Jul-Aug;(4):46, 48-50, 52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The experience in dutasteride use before transurethral prostatic resection for large adenoma].
  • Dutasterid is a novel effective inhibitor of 5-alpha reductase of both types which can be used in patients with large (more than 80 cm3) prostatic adenoma to prevent intra- and postoperative hemorrhagic complications before transurethral resection of the prostate (TUR).
  • The trial included 70 males aged 67-82 years (mean age 74 years) with large size prostatic adenoma (more than 80 cm3) having indications for prostatic TUR.
  • Patients with coagulopathy, suspected prostatic cancer, previous treatment with 5-alpha reductase inhibitors were not included.
  • We recommend to begin dutasterid administration in a dose 0.5 mg for 1 month before TUR not only for patients with larger prostate (greater than 80 cm3) but with smaller prostates (30-80 cm3) for prevention of hemorrhagic complications and better conditions for surgery.
  • [MeSH-major] Azasteroids / administration & dosage. Enzyme Inhibitors / administration & dosage. Preoperative Care. Prostatic Hyperplasia / surgery. Urogenital Surgical Procedures

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19054996.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Azasteroids; 0 / Enzyme Inhibitors; O0J6XJN02I / Dutasteride
  •  go-up   go-down


9. Gkritsios P, Fotas A, Bekas M, Adamou V, Katsikas V: Thirty years old man with a huge benign prostatic enlargement. Arch Ital Urol Androl; 2010 Jun;82(2):116-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thirty years old man with a huge benign prostatic enlargement.
  • Imaging revealed an enormous prostatic mass.
  • Combining this finding with elevated PSA values, lead us to prostatic biopsies which proved to be benign.
  • Following our advice, the patient had children and afterwards he had his prostate removed.
  • The suprapubic prostatectomy was extremely challenging with a lot of technical difficulties, considering that the net weight of the removed adenoma was 250gr.
  • Pathological examination of the tissue proved that it was benign prostatic hyperplasia.
  • Our case is particularly interesting for two reasons: On one hand because of the unusual size of the prostate and on the other hand because of the young age of the patient.
  • Epidemiological studies showed that prostatic hyperplasia has been pathologically proved only after the age of 40, while pathological signs of the disease could be found after the age of 30.
  • Concerning the size of the adenoma, a search in the literature showed that only 4% of the removed glands weight more than 100 gr, and that has to do with men over 70 years of age.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20812537.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Kolbasov DN: [Hyperbaric oxygenation in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):92-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hyperbaric oxygenation in patients with prostatic adenoma].
  • [MeSH-major] Hyperbaric Oxygenation. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526884.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 41
  •  go-up   go-down


11. Skolarikos A, Papachristou C, Athanasiadis G, Chalikopoulos D, Deliveliotis C, Alivizatos G: Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol; 2008 Oct;22(10):2333-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc.
  • CONFLICT OF INTEREST: None Take Home Message: This is a prospective randomized study showing that for large prostatic adenomas, photoselective vaporization of the prostate requires less blood transfusions, shorter catheterization time and shorter hospital stay compared to open prostatectomy, while achieving similar functional results at the same time.
  • AIM: The effectiveness and the safety of photoselective vaporization of the prostate (PVP) was compared to that of open prostatectomy (OP) for the surgical treatment of large prostatic adenomas.
  • METHODS: 125 patients with prostate glands>80 ml, were randomly allocated to PVP (n=65) or OP (n=60) and prospectively evaluated at 1, 3, 6, 12, and 18 months postoperatively.
  • International prostate symptom score (IPSS) and peak urinary flow rate (Qmax) were chosen as primary treatment-related endpoints.
  • At three months prostate volume was significantly lower in the OP group and remained as such throughout follow-up.
  • CONCLUSIONS: Our results indicate that for an 18 month period photoselective vaporization of the prostate is a highly acceptable treatment alternative to open prostatectomy.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837655.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


12. Shimizu Y, Hiraoka Y, Iwamoto K, Takahashi H, Abe H, Ogawa H: Is complete resection of hypertrophic adenoma of the prostate possible with TURP? J Nippon Med Sch; 2005 Jun;72(3):146-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is complete resection of hypertrophic adenoma of the prostate possible with TURP?
  • A lot of adenoma remains after transurethral resection of the prostate (TURP), the other hand transurethral enucleation of the prostate (TUE) is useful for complete resection of an adenoma.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods
  • [MeSH-minor] Biomarkers / blood. Humans. Male. Prostate / pathology. Prostate / ultrasonography. Prostate-Specific Antigen / blood. Recurrence

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046830.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 15
  •  go-up   go-down


13. Lee YH, Chiu AW, Huang JK: Comprehensive study of bladder neck contracture after transurethral resection of prostate. Urology; 2005 Mar;65(3):498-503; discussion 503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive study of bladder neck contracture after transurethral resection of prostate.
  • OBJECTIVES: To test the validity of transurethral resection of the prostate (TURP) plus transurethral incision (TUI) of bladder neck as an alternative to TUI of the prostate, a nonrandomized and retrospective study was done to review comprehensively the incidence of, severity of, and risk factors for bladder neck contracture (BNC) in patients with benign prostatic hyperplasia who underwent transurethral surgery.
  • METHODS: The evaluation parameters included age, prostate-specific antigen level, urinalysis and uroflowmetry findings, voided volume, presence of vesical stones and urinary retention, surgical type, adenoma weight, and perioperative morbidities.
  • The adenoma weight, blood transfusion, and postoperative maximal and mean flow rate in patients with BNC were significantly less than in patients without BNC.
  • BNC was completely prevented using TURP plus TUI if the adenoma weight was greater than 30 g.
  • However, in the TURP group, 4% of patients developed BNC even with an adenoma weight greater than 50 g.
  • Multivariate analyses showed that adenoma weight and surgical type were significant risk factors for BNC.
  • CONCLUSIONS: TURP plus TUI provides a pathologic diagnosis, and with minimal morbidity, it can be an alternative to TUI of the prostate in selected patients.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / adverse effects. Urinary Bladder Diseases / etiology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780363.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Arbuliev MG, Zaĭnulabidov ZSh, Mukhamad II, Arbuliev KM: [A variant of transvesical extraurethral adenomectomy]. Urologiia; 2007 Jul-Aug;(4):37-9, 41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To facilitate extraurethral adenomectomy, we used a semicylindric scalpel and metallic tube (tubus) to make a semioval cut parallel to proximal prostatic portion of the urethra along the posterior semicircle of the bladder neck in 260 patients with prostatic adenoma (PA).
  • Extra-urethral adenomectomy with semicylindric scalpel injured prostatic urethra in lesser extent than endourethral adenomectomy, it reduced the risk of hemorrhage, entailed neither stricture of the posterior urethra nor incontinence of urine in the postoperative period.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Urologic Surgical Procedures, Male / instrumentation. Urologic Surgical Procedures, Male / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915447.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


15. Abdel-Khalek M, Sheir KZ, El-Baz M, Ibrahiem el-H: Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen &gt;10 ng/ml and prior negative peripheral zone biopsy? Scand J Urol Nephrol; 2005;39(1):49-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
  • OBJECTIVES: To evaluate the importance of transition zone (TZ) biopsy in benign prostatic hyperplasia (BPH) patients with serum prostate-specific antigen (PSA) >10 ng/ml and prior negative peripheral zone (PZ) biopsy and to estimate the sensitivity of TZ biopsy.
  • Overall, 215 patients were subjected to either transurethral resection of the prostate (n=162) or open enucleation of the adenoma (n=53).
  • RESULTS: The extended biopsy revealed prostate cancers in 21.2% of cases (58/273).
  • Prostate volume (p=0.023), TZ volume (p=0.027) and PSA/TZ density (p=0.007) were predictive of TZ cancers.
  • [MeSH-major] Biomarkers, Tumor / blood. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / pathology
  • [MeSH-minor] Aged. Biopsy. Humans. Incidence. Male. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / epidemiology. Sensitivity and Specificity


16. Davidov MI: [Factors predisposing to acute urine retention in patients with prostatic adenoma]. Urologiia; 2007 Mar-Apr;(2):25-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Factors predisposing to acute urine retention in patients with prostatic adenoma].
  • The aim of the trial was to study factors predisposing to acute urine retention (AUR) in patients with prostatic adenoma (PA).
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Retention / epidemiology. Urinary Retention / etiology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580384.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


17. Morgunov LIu, Vertkin AL, Pushkar' DIu: [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency]. Urologiia; 2007 Sep-Oct;(5):49-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Safety of testosterone undecanoate in relation to initiation of cancer and prostatic adenoma (PA) in patients with androgenic deficiency and erectile dysfunction (ED) was studied for 12 months in 49 patients aged 57 to 73 years treated with intramuscular testosteron injections.
  • The size of the prostate in patients with adenoma was 46.34 +/- 21.12 cm3 while in adenoma-free patients--19.11 +/- 6.57 sm3.
  • Thus, long-term therapy with testosterone undecanoate has no effect on PSA level, does not induce urinary obstruction with enlarged prostate.
  • The presence of DM-2 is not a contraindication for androgen therapy in adenoma patients.
  • By reducing body mass index, total cholesterol, triglycerides and LDLP, testosterone therapy lowers the risk of prostatic cancer.
  • [MeSH-minor] Aged. Diabetes Mellitus, Type 2 / complications. Diabetes Mellitus, Type 2 / diagnosis. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Prostatic Hyperplasia / chemically induced. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / chemically induced. Prostatic Neoplasms / diagnosis


18. Aliaev IuG, Vinarov AZ, Lokshin KL, Spivak LG: [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy]. Urologiia; 2007 Mar-Apr;(2):80-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy].
  • [MeSH-major] Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy. Serenoa / chemistry

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578203.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts
  • [Number-of-references] 33
  •  go-up   go-down


19. Alivizatos G, Skolarikos A, Chalikopoulos D, Papachristou C, Sopilidis O, Dellis A, Kastriotis I, Deliveliotis C: Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas &gt;80ml: 12-mo results of a randomized prospective study. Eur Urol; 2008 Aug;54(2):427-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study.
  • OBJECTIVES: To compare the effectiveness and the safety of photoselective vaporization of the prostate (PVP) to open prostatectomy (OP) for the surgical treatment of large prostatic adenomas.
  • METHODS: A total of 125 patients with prostate glands >80ml were randomly allocated to PVP (n=65) or OP (n=60) and prospectively evaluated at 1, 3, 6, and 12 mo postoperatively.
  • International Prostate Symptom Score (IPSS) and peak urinary flow rate (Q(max)) were chosen as primary treatment-related end points.
  • At 3 mo prostate volume was significantly lower in the OP group compared to the PVP group (median value 10ml vs. 50ml; p<0.001) and remained as such throughout follow-up, whereas prostate-specific antigen values reached statistical difference at 6 mo (median value 2ng/ml vs. 2.4ng/ml; p=0.028).
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2008 Aug;54(2):435-6 [18069122.001]
  • [CommentIn] Eur Urol. 2008 Aug;54(2):436-7 [18069121.001]
  • (PMID = 18069117.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Lopatkin NA, Petrov SB, Sivkov AV, Markov AV, Oshchepkov NN, Bolokhanov IuN: [Pilot results of using tamsulone-FS in patients with prostatic adenoma according to the results of a randomized multicenter comparative trial]. Urologiia; 2006 May-Jun;(3):3-6, 8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pilot results of using tamsulone-FS in patients with prostatic adenoma according to the results of a randomized multicenter comparative trial].
  • Tamsulone-FS--a novel Russian alpha1A/D-adrenoblocker (Farm-Syntez)--was studied in a randomized multicenter comparative trial in patients with prostatic adenoma.
  • Pilot results agreed with other trials published in the literature and demonstrated tamsulone-FS efficacy and safety for management of lower urinary tract symptoms caused by prostatic adenoma.
  • This drug can be recommended for wide clinical practice in prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Antineoplastic Agents / therapeutic use. Prostatic Hyperplasia / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889080.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Antineoplastic Agents; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


21. Pantuck AJ, Baniel J, Kirkali Z, Klatte T, Zomorodian N, Yossepowitch O, Belldegrun AS: A novel resectoscope for transurethral resection of bladder tumors and the prostate. J Urol; 2007 Dec;178(6):2331-6; discussion 2336
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel resectoscope for transurethral resection of bladder tumors and the prostate.
  • Transurethral prostate resection may be complicated by inadvertent damage to the urinary sphincter, bladder neck and trigone.
  • It consists of variably sized cutting loops designed for transurethral resection of bladder tumors and the prostate.
  • To date 80 patients with bladder cancer (38) or benign prostatic hyperplasia (42) have undergone surgery with this instrument at our 3 clinical sites.
  • During transurethral prostate resection this novel tool facilitated dissection of adenoma adjacent to the verumontanum and prostatovesical junction, which may decrease the risk of sphincteric damage and bladder neck injury.
  • Current data suggest that the learning curve is mild, its use is safe and it provides distinct advantages when used for transurethral resection of bladder tumors and the prostate.
  • [MeSH-major] Endoscopes. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Transurethral Resection of Prostate / instrumentation. Urinary Bladder Neoplasms / surgery


22. Shimizu Y, Hiraoka Y, Iwamoto K, Takahashi H, Abe H: Measurement of residual adenoma after transurethral resection of the prostate by transurethral enucleation technique. Urol Int; 2005;74(2):102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of residual adenoma after transurethral resection of the prostate by transurethral enucleation technique.
  • OBJECTIVE: Transurethral resection of the prostate (TURP) leaves a lot of residual adenoma and has a high recurrence rate, but the residual adenoma weight has not been measured surgically.
  • Using surgery we tried to measure the residual adenoma after TURP.
  • MATERIAL AND METHODS: Total adenoma resection was performed via standard TURP in 64 cases with benign prostatic hyperplasia and the weight of the residual adenoma was measured by transurethral enucleation (TUE) of the prostate.
  • RESULTS: Prostate volume averaged 37.4 ml and adenoma volume averaged 20.6 ml by TRUS.
  • The average weight of the prostate removed by TURP was 9.8 g.
  • After TURP residual adenoma was confirmed in all cases by TUE, and the average weight of the residual adenoma was 10.2 g.
  • The total average prostate volume removed by TURP and TUE was 20.1 g.
  • The average residual rate of the adenoma removed by TURP was 54.5%.
  • CONCLUSION: TURP leaves about half of the adenoma.
  • Therefore, TURP might be very difficult for complete resection of an adenoma.
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756059.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Martov AG, Merinov DS, Borisenko EA: [Transurethral plasmokinetic resection and vaporization is a new method of treatment of prostatic adenoma]. Urologiia; 2006 May-Jun;(3):12-3, 15-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral plasmokinetic resection and vaporization is a new method of treatment of prostatic adenoma].
  • Clinical efficacy and safety ofplasmakinetic resection and vaporization were studied in 28 patients with prostatic adenoma (mean age 68 years, mean size of the prostate 65 cm3).
  • Complaints by IPSS scale, quality of life index, results of uroflowmetry and prostatic ultrasonography were assessed before surgery (transurethral plasmakinetic resection and prostatic vaporization) and 1, 3, 6 and 12 months after it.
  • Pilot results point to high clinical efficacy and safety of plasmakinetic resection and vaporization in patients with prostatic adenoma.
  • [MeSH-major] Laser Therapy / methods. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889082.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


24. Al'-Shukri SKh, Gorbachev AG, Borovets SIu, Belousov VIa, Kuz'min IV, Chushkin KA: [Prostatilen treatment of prostatic adenoma]. Urologiia; 2006 Nov-Dec;(6):22, 25-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatilen treatment of prostatic adenoma].
  • We studied efficacy of repeated courses of prostatilen in suppositories with dimexide in prostatic adenoma patients with normal micturition.
  • This suggests possibility of suppository prostatilen use not only as an alternative for expensive drugs but also in combination with them in treatment of initial prostatic adenoma.
  • [MeSH-major] Peptides / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315707.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Peptides; 0 / Suppositories; 0 / prostatilen; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


25. Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C: Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial. Urology; 2008 Feb;71(2):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial.
  • OBJECTIVES: To compare the short term outcomes of photoselective vaporization (PVP) and transurethral resection of the prostate (TURP) for glands larger than 70 mL in a prospective randomized trial.
  • METHODS: Seventy-six consecutive patients with enlarged prostatic adenomas of 70 to 100 mL were randomly assigned for surgical treatment with TURP (n = 37) or PVP (n = 39).
  • International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-5) scores, maximum flow rates (Qmax), postvoid urine residues (PVR), and transrectal ultrasound (TRUS) volumes were recorded.
  • [MeSH-major] Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Urology. 2008 Sep;72(3):718-9 [18597826.001]
  • (PMID = 18308094.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


26. Cohen RJ, Shannon BA: Tubulovillous adenoma of the prostatic urethra: a rare and usually indolent lesion distinct from prostatic adenocarcinoma. Pathology; 2007 Oct;39(5):522-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulovillous adenoma of the prostatic urethra: a rare and usually indolent lesion distinct from prostatic adenocarcinoma.
  • [MeSH-major] Adenoma / pathology. Diverticulum / pathology. Prostatic Neoplasms / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886106.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


27. Halsey MA, Calder KB, Mathew R, Schlauder S, Morgan MB: Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms. J Cutan Pathol; 2010 Apr;37(4):446-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AMACR has been established as a valuable diagnostic marker for prostate cancer and has recently been shown to be useful in the diagnosis of colorectal carcinoma.
  • METHODS: Five samples of normal sebaceous glands as well as five cases each of sebaceous hyperplasia (SH), sebaceous adenoma (SA), basal cell carcinoma (BCC) with sebaceous differentiation and extraocular sebaceous carcinoma (SC) were evaluated for immunohistochemical (IHC) expression of AMACR.
  • CONCLUSIONS: The expression of AMACR is increased in benign sebaceous glands and SH; with decreasing AMACR expression in tumors with less sebaceous differentiation (i.e.
  • [MeSH-major] Adenoma / enzymology. Carcinoma / enzymology. Racemases and Epimerases / metabolism. Sebaceous Gland Neoplasms / enzymology. Sebaceous Glands / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638170.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


28. Miller AM, Iaroshenko VP, Soroka PV, Stakhnev EIu: [Efficacy of vitaprost forte in patients with prostatic adenoma]. Urologiia; 2008 Sep-Oct;(5):50, 52-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of vitaprost forte in patients with prostatic adenoma].
  • The trial of a new bioregulatory peptide vitaprost forte (100 mg rectal suppositoria) in 30 patients with prostatic adenoma demonstrated that this drug attenuates clinical symptoms of the disease, improves quality of life, uroflowmetric parameters and reduces size of the prostate.
  • Vitaprost forte is more effective in patients with prostatic adenoma in combination with chronic prostatitis, has antiaggregant and anticoagulant properties, stimulates synthesis of antihistamine and antiserotonine antibodies, improves microcirculation in the prostate resulting in regressioin of edema, activity of inflammation in prostatic diseases.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069497.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


29. Oreste M, Giuseppe PG, Gianna P, Adriano A, Stefano N, Mauro B, Carlo V: Between-subject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia. World J Urol; 2010 Jun;28(3):379-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Between-subject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia.
  • PURPOSE: We verified if the measure of transition zone epithelial volume (TZepiV) could be a valid predictor of serum PSA value in men with benign prostatic hyperplasia (BPH).
  • In case of an elevated PSA level (above 4 ng/ml) or abnormal digital rectal examination, systematic multisite biopsies were performed preoperatively to rule out prostate cancer.
  • We have examined PSA levels before and after open surgery, TZ weight as measured by the pathologist and TZepiV by multiplying percentage of epithelium of a single biopsy core with the weight of adenoma.
  • The mean decrease in PSA was 90% (range 70-99%).The mean weight of enucleated adenoma was 67 gr.(range 18-201) and the TZepiV was 7.7 ml (0.3-28.4).
  • Thus, TZ epithelial volume could represent a new useful clinical tool able to increase the specificity of PSA in the diagnosis of prostate cancer.
  • [MeSH-major] Adenoma / blood. Adenoma / pathology. Epithelium / pathology. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Needle. Cohort Studies. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Probability. Prostatectomy / methods. Retrospective Studies. Risk Assessment. Transurethral Resection of Prostate / methods. Treatment Outcome. Tumor Burden


30. Xiao GQ, Burstein DE, Miller LK, Unger PD: Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma. Arch Pathol Lab Med; 2006 Jun;130(6):805-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
  • CONTEXT: Nephrogenic adenoma is a rare benign lesion of the urinary tract.
  • Owing to its strong association with a history of urinary tract irritation, nephrogenic adenoma was initially thought to originate from urothelial metaplasia; however, no solid proof of this association has been found.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic carcinoma, particularly when dealing with lesions from the prostatic urethra.
  • OBJECTIVE: To elucidate a possible histogenic relationship between nephrogenic adenoma and renal tubules, and also to evaluate the role of immunohistochemistry in the diagnostic distinction between nephrogenic adenoma and prostate carcinoma.
  • DESIGN: Immunohistochemical studies were performed for P504S, prostate-specific antigen, CD10, p63, and epithelial membrane antigen on 9 cases of nephrogenic adenoma, 10 cases of normal renal parenchyma, and 10 cases of prostatic tissue, both benign and malignant.
  • RESULTS: Nephrogenic adenoma shares the same immunohistochemical profile as distal renal tubules: both are positive for P504S and epithelial membrane antigen and negative for p63, CD10, and prostate-specific antigen.
  • Prostatic adenocarcinoma tissue was positive for P504S and prostate-specific antigen, and normal prostatic gland tissue was positive for prostate-specific antigen and negative for P504S; p63-stained basal cells in normal prostatic gland tissue but did not react with prostatic adenocarcinoma tissue.
  • The CD10 inconsistently stained normal and neoplastic prostatic gland tissue.
  • Epithelial membrane antigen stain was negative in prostatic carcinoma, with rare occasional reactivity in normal prostatic glands.
  • CONCLUSION: These findings provide supporting evidence that nephrogenic adenoma is derived from distal renal tubules.
  • Our results also demonstrated that the combination of P504S and prostate-specific antigen with epithelial membrane antigen is a valuable tool in distinguishing prostatic carcinoma from nephrogenic adenoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Immunohistochemistry / methods. Prostatic Neoplasms / diagnosis. Urologic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Mucin-1 / analysis. Racemases and Epimerases / analysis. Urothelium / chemistry. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740031.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


31. Shriki J, Murthy V, Brown J: Renal oncocytoma on 1-11C acetate positron emission tomography: Case report and literature review. Mol Imaging Biol; 2006 Jul-Aug;8(4):208-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although generally benign, these tumors pose a diagnostic and therapeutic dilemma in that they can not be differentiated noninvasively from renal cell carcinomas.
  • We report a 67-year-old man who underwent a clinical 1-11C acetate positron emission tomography (PET) scan for evaluation of possible metastatic prostate carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / diagnostic imaging. Kidney Neoplasms / diagnostic imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):871-83 [9255250.001]
  • [Cites] J Urol. 1991 Mar;145(3):552-4 [1997708.001]
  • [Cites] Pathology. 1982 Jan;14(1):75-80 [7078991.001]
  • [Cites] Radiology. 1978 Dec;129(3):615-22 [725034.001]
  • [Cites] Diagn Interv Radiol. 2005 Mar;11(1):35-40 [15795842.001]
  • [Cites] AJR Am J Roentgenol. 1996 Sep;167(3):771-6 [8751698.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S153-8 [15508079.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):602-4 [14713769.001]
  • [Cites] Circulation. 1987 Sep;76(3):687-96 [3113765.001]
  • [Cites] Carcinogenesis. 2003 Sep;24(9):1461-6 [12844484.001]
  • [Cites] J Nucl Med. 2003 Apr;44(4):549-55 [12679398.001]
  • [Cites] Cytogenet Cell Genet. 1994;66(4):253-9 [7909283.001]
  • [Cites] Cancer. 1976 Aug;38(2):906-14 [975006.001]
  • [Cites] J Nucl Med. 1995 Sep;36(9):1595-601 [7658216.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 21;302(4):898-903 [12646257.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1236-45 [12845486.001]
  • [Cites] J Nucl Med. 2001 Aug;42(8):1174-82 [11483676.001]
  • [Cites] Eur J Nucl Med. 2001 May;28(5):651-68 [11383873.001]
  • [Cites] Nucl Med Biol. 2002 Jul;29(5):613-21 [12088733.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):759-68 [12016148.001]
  • [Cites] Radiology. 1993 Mar;186(3):693-6 [8430176.001]
  • [Cites] AJR Am J Roentgenol. 1984 Nov;143(5):1001-4 [6385667.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):1-12 [8990136.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jan;31(1):13-21 [14574513.001]
  • [Cites] Nucl Med Biol. 2001 Feb;28(2):117-22 [11295421.001]
  • [Cites] Abdom Imaging. 1998 Jul-Aug;23 (4):431-6 [9663282.001]
  • [Cites] Urol Radiol. 1980-1981;2(4):229-34 [7022993.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jan;186(1):269-70 [16357422.001]
  • [Cites] J Urol. 1999 Oct;162(4):1246-58 [10492174.001]
  • [Cites] J Nucl Med. 2002 Feb;43(2):181-6 [11850482.001]
  • [Cites] J Urol. 1996 Mar;155(3):863-7 [8583594.001]
  • (PMID = 16791747.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes
  •  go-up   go-down


32. Yuh B, Laungani R, Perlmutter A, Eun D, Peabody JO, Mohler JL, Stricker H, Guru KA: Robot-assisted Millin's retropubic prostatectomy: case series. Can J Urol; 2008 Jun;15(3):4101-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION/OBJECTIVE: Simple prostatectomy continues to be an effective surgical option for patients with symptomatic high volume benign prostatic hyperplasia.
  • Recent trends towards minimally invasive urologic surgery, in particular for prostate cancer, have created surgical alternatives with additional potential benefits.
  • Average preoperative transrectal ultrasound estimated prostate volume exceeded 300 cm3.
  • RESULTS: Average age for the patient group was 76.7 years with mean prostate specific antigen (PSA) of 25.1.
  • The patient with the largest prostate required incision extension for removal of specimen.
  • Average adenoma weight was 301 grams (66-640).
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Prostatic Hyperplasia

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570717.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


33. Csomor J, Kaszás I, Kollár B, Pajor L, Egyházi Z, Fekete S, Egyed M, Timár B: Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma. Pathol Oncol Res; 2008 Sep;14(3):281-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma.
  • Here we report a case of a 73-year-old man with primary intravascular large B-cell lymphoma localized to the prostate.
  • Total prostatectomy was performed due to a benign adenoma suggested by ultrasonography.
  • The diagnosis of IVLBL was obtained incidentally from the prostatectomy specimen.
  • Primary prostate IVLBL is extremely uncommon; to date only four cases have been described.
  • Successful treatment depends on early diagnosis of IVLBL, aggressive chemotherapy and the fact that IVLBL should be considered as a generalized disease in spite of negative staging results.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2004 May 01;89(5):ECR13 [15136242.001]
  • [Cites] Br J Haematol. 2007 Mar;136(5):684 [17129231.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):173-83 [15461623.001]
  • [Cites] Br J Haematol. 2002 Oct;119(1):2 [12358897.001]
  • [Cites] Oncologist. 2006 Sep;11(8):923-8 [16951396.001]
  • [Cites] Hum Pathol. 2000 Feb;31(2):220-6 [10685637.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):564-5 [12560450.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2005 Mar;34(3):189-90 [15938838.001]
  • [Cites] Int J Hematol. 2006 Jul;84(1):74-8 [16867907.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):693-9 [15832096.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):732-8 [9708938.001]
  • [Cites] Rev Med Chil. 2004 Nov;132(11):1403-6 [15693204.001]
  • (PMID = 18493873.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; IEV protocol
  •  go-up   go-down


34. Talmant V, Esposito P, Stilhart B, Mohr M, Tranchant C: [Subthalamic stimulation in a patient with multiple system atrophy: a clinicopathological report]. Rev Neurol (Paris); 2006 Mar;162(3):363-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He developed severe urinary disorders increased by a prostatic adenoma which led to surgical treatment.
  • [MeSH-minor] Adenoma / surgery. Antiparkinson Agents / therapeutic use. Biomarkers. Brain / pathology. Brain Chemistry. Combined Modality Therapy. Diagnostic Errors. Disease Progression. Fatal Outcome. Humans. Levodopa / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Parkinson Disease / diagnosis. Parkinson Disease / drug therapy. Parkinson Disease / therapy. Prostatectomy. Prostatic Neoplasms / surgery. Substantia Nigra / pathology. Ubiquitin / analysis. alpha-Synuclein / analysis

  • Genetic Alliance. consumer health - Multiple system atrophy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585892.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; Clinical Conference; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 0 / Biomarkers; 0 / Ubiquitin; 0 / alpha-Synuclein; 46627O600J / Levodopa
  •  go-up   go-down


35. Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC: Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol; 2005 Oct 1;23(28):6846-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A diagnosis was obtained in 69 of these patients, including 37 (54%) with solitary metastases and 32 (46%) with lesions unrelated to the lung primary.
  • Histopathologic examinations of these 32 lesions revealed a second clinically unsuspected malignancy or a recurrence of a previous diagnosed carcinoma in six patients (19%) and a benign tumor or inflammatory lesion in 26 patients (81%).
  • The six malignancies consisted of carcinoma of the breast in two patients, and carcinoma of the orbit, esophagus, prostate, and non-Hodgkin's lymphoma in one patient each.
  • Benign tumors and inflammatory lesions included eight colon adenomas, four Warthin's tumors, one granuloma of the lower jaw, one adenoma of the thyroid gland, one compensatory muscle activity due to vocal chord palsy, two occurrences of arthritis, three occurrences of reflux esophagitis, two occurrences of pancreatitis, two occurrences of diverticulitis, one hemorrhoidal inflammation, and one rib fracture.
  • CONCLUSION: Solitary extrapulmonary FDG accumulations in patients with newly diagnosed lung cancer should be analyzed critically for correct staging and optimal therapy, given that up to half of the lesions may represent unrelated malignancies or benign disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Inflammation. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192576.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


36. Shaked G, Czeiger D: Distended urinary bladder and diverticulum-a rare cause of large-bowel obstruction. Am J Surg; 2009 Feb;197(2):e23-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Later the patient underwent surgery to remove an enlarged benign prostatic adenoma, which was the underlying cause of the bladder distention.
  • [MeSH-major] Dilatation, Pathologic / etiology. Diverticulum / complications. Intestinal Obstruction / etiology. Prostatic Hyperplasia / complications. Urinary Bladder Diseases / etiology


37. Matlaga BR, Miller NL, Lingeman JE: Holmium laser treatment of benign prostatic hyperplasia: an update. Curr Opin Urol; 2007 Jan;17(1):27-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Holmium laser treatment of benign prostatic hyperplasia: an update.
  • PURPOSE OF REVIEW: The surgical treatment of benign prostatic hyperplasia is a dynamic, evolving field.
  • Holmium laser enucleation of the prostate has been one of the most rigorously analyzed interventions for benign prostatic hyperplasia.
  • RECENT FINDINGS: In the 12-month period of this review, there have been a number of articles published on holmium laser enucleation of the prostate.
  • These studies emphasize the unique advantages of holmium laser enucleation of the prostate over other surgical treatments for benign prostatic hyperplasia.
  • SUMMARY: Holmium laser enucleation of the prostate is a more efficient procedure than competitor techniques, when grams of tissue removed per unit time are quantified.
  • Additionally, holmium laser enucleation of the prostate is associated with a reduced length of catheterization and hospitalization when compared with other surgical therapies for men with benign prostatic hyperplasia.
  • Outcome measures for men undergoing holmium laser enucleation of the prostate are in many cases superior to those of other modalities.
  • It is likely that the completeness of adenoma removal with holmium laser enucleation of the prostate confers many of these advantages.
  • [MeSH-major] Holmium. Laser Therapy / trends. Prostate / surgery. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / trends

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143108.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] W1XX32SQN1 / Holmium
  • [Number-of-references] 18
  •  go-up   go-down


38. Klausner AP, Anderson BB, Espy PG, Despradel VM, Grob BM: Long term prostate-specific antigen trends following subcapsular prostatectomy. Can J Urol; 2010 Dec;17(6):5442-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term prostate-specific antigen trends following subcapsular prostatectomy.
  • INTRODUCTION: The purpose of this study was to evaluate the utility of prostate-specific antigen (PSA) screening for prostate cancer after subcapsular prostatectomy.
  • Patients were categorized into benign and malignant groups based on a diagnosis of prostate cancer identified in the surgical specimen or during subsequent follow up.
  • Collected data included patient age, preoperative and postoperative PSA values, prostate volume determined by surgical specimen weight, and pathologic diagnosis.
  • Preoperative and postoperative PSA velocities were calculated for patients with adequate data and average values were compared to determine factors that were predictive of a confirmed prostate cancer diagnosis.
  • Six (19%) were ultimately diagnosed with prostate cancer and 25 (81%) were never diagnosed with prostate cancer.
  • Postoperative PSA velocity was found to be significantly higher for patients in the malignant group (1.22 ± 1.32 ng/mL/yr) as compared to patients in the benign group (0.06 ± 0.15 ng/mL/yr) (p = 0.003).
  • CONCLUSIONS: After subcapsular prostatectomy, patients with prostate cancer in the surgical specimen or who developed prostate cancer during long term follow up had elevated PSA velocity compared to patients who had no evidence of cancer in the surgical specimen or in follow up.
  • [MeSH-major] Adenoma / blood. Prostate-Specific Antigen / blood. Prostatectomy / methods. Prostatic Hyperplasia / blood. Prostatic Neoplasms / blood


39. Sotelo R, Clavijo R, Carmona O, Garcia A, Banda E, Miranda M, Fagin R: Robotic simple prostatectomy. J Urol; 2008 Feb;179(2):513-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Minimally invasive approaches for large, symptomatic benign prostatic hyperplasia are replacing the gold standard open surgical approach, duplicating its results with lower morbidity.
  • Considerable improvement from baseline was noted in International Prostate Symptom Score (preoperative vs postoperative 22 vs 7.25) and maximum urine flow (preoperative vs postoperative 17.75 vs 55.5 ml per minute).
  • Further publications are expected with larger series and larger prostatic adenomas.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Robotics

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2008 Oct;180(4):1569-70; author reply 1570 [18718613.001]
  • (PMID = 18076926.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Seki N, Nomura H, Yamaguchi A, Naito S: Evaluation of the learning curve for photoselective vaporization of the prostate over the course of 74 cases. J Endourol; 2008 Aug;22(8):1731-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the learning curve for photoselective vaporization of the prostate over the course of 74 cases.
  • PURPOSE: To evaluate the learning experience, in addition to its impact on outcomes, in patients with benign prostatic hyperplasia (BPH) who undergo photoselective vaporization of the prostate (PVP).
  • All patients were assessed for treatment efficacy in outcome variables including the International Prostate Symptom Score (IPSS), quality-of-life (QOL) score, peak urinary flow rate (Q(max)), and post-void residual urine volume (PVR) at 12 months after PVP.
  • The time required for tissue vaporization of the adenoma and the total applied laser energy, along with the vaporized weight, significantly increased, but the efficiency of tissue vaporization did not increase as experience increased.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681811.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Apolikhin OI, Sivkov AV, Beshliev DA, Abdullin II: [Current opportunities of pharmacotherapy of prostatic adenoma]. Urologiia; 2010 Mar-Apr;(2):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current opportunities of pharmacotherapy of prostatic adenoma].
  • [MeSH-major] 5-alpha Reductase Inhibitors / therapeutic use. Adrenergic alpha-Antagonists / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20967996.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


42. Kamalov AA, Efremov EA, Dorofeev SD, Mel'nik IaI, Okhobotov DA: [Vitaprost forte in the therapy of patients with prostatic adenoma]. Urologiia; 2007 May-Jun;(3):39-44, 47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vitaprost forte in the therapy of patients with prostatic adenoma].
  • Active substance of the drug vitaprost is a complex of water-soluble biologically active peptides isolated from bovine prostatic gland.
  • Prostatic extract has an organotropic effect in respect to the prostatic gland.
  • It inhibits proliferative activity of cells and, therefore, development of prostatic adenoma, reduces edema and inflammation activity in prostatic diseases.
  • Our study has shown that rectal suppositories vitaprost forte, as monotherapy of prostatic adenoma, produces a statistically significant moderate decrease of prostate size.
  • Rectal suppositories vitaprost forte can be used as monotherapy of prostatic adenoma in patients with moderate infravesical obstruction irrespective of age and concurrent diseases.
  • [MeSH-major] Peptides / therapeutic use. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Animals. Cattle. Drug Administration Schedule. Humans. Male. Organ Size. Prostate / chemistry. Prostate / pathology. Sulfonamides / administration & dosage. Sulfonamides / therapeutic use. Suppositories. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722619.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Sulfonamides; 0 / Suppositories; 0 / Vitaprost; G3P28OML5I / tamsulosin
  •  go-up   go-down


43. Borisov VB: [Treatment of prostatic adenoma]. Urologiia; 2010 Jul-Aug;(4):42-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of prostatic adenoma].
  • We used lymphotropic therapy in addition to standard treatment in 116 of 232 patients with benign prostatic hyperplasia.
  • Improvement in general condition of the patients, symptoms of infravesical obstruction, size of the prostate, urinary flow rate demonstrated high efficacy of lymphotropic therapy leading to a higher rate of persistent remission and higher quality of life.
  • [MeSH-major] 5-alpha Reductase Inhibitors / therapeutic use. Adrenergic alpha-1 Receptor Antagonists / therapeutic use. Anti-Bacterial Agents / therapeutic use. Finasteride / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20967982.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adjuvants, Immunologic; 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Sulfonamides; 57GNO57U7G / Finasteride; EC 3.2.1.- / lidase; EC 3.2.1.35 / Hyaluronoglucosaminidase; G3P28OML5I / tamsulosin
  •  go-up   go-down


44. Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E, Lecellier G, Rebouillat D, Lemaire C, Kroemer G, Jacotot E, Brenner C: Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res; 2006 Sep 15;66(18):9143-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most importantly, ANT2, but not ANT1, silencing facilitated MMP induction by lonidamine, a mitochondrion-targeted antitumor compound already used in clinical studies for breast, ovarian, glioma, and lung cancer as well as prostate adenoma.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982757.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotide Translocator 1; 0 / Adenine Nucleotide Translocator 2; 0 / Antineoplastic Agents; 0 / Indazoles; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; 8L70Q75FXE / Adenosine Triphosphate; U78804BIDR / lonidamine
  •  go-up   go-down


45. Miller AM: [The experience in postoperative administration of alpha-adrenoblockers]. Urologiia; 2007 Sep-Oct;(5):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study of efficacy of alpha-blocker alfuzosine (dalphaz CP) in a dose 10 mg/day for treatment of postoperative complications after transurethral resection (TUR) of the prostate and open adenomectomy (OAE) and in quality of life (QoL) improvement enrolled 22 patients after TUR of the prostate and 18 patients after OAE.
  • Administration of alpha-blocker on day 1 after surgical treatment of prostatic adenoma leads to earlier regress of urination disorders.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Quinazolines / therapeutic use. Transurethral Resection of Prostate. Urination Disorders / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • Hazardous Substances Data Bank. ALFUZOSIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254227.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Quinazolines; 90347YTW5F / alfuzosin
  •  go-up   go-down


46. Protogerou V, Argyropoulos V, Patrozos K, Tekerlekis P, Kostakopoulos A: An alternative minimally invasive technique for large prostates (&gt;80 mL): transvesical prostatectomy through a 3-cm incision. Urology; 2010 Jan;75(1):184-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 165 patients with benign prostatic hyperplasia were treated with transvesical prostatectomy through a 3-cm incision.
  • Prostate size was 85-144 cm(3) (mean 101 cm(3)).
  • Prostate adenoma was removed with finger dissection without the placement of hemostatic sutures.
  • [MeSH-major] Prostatectomy / methods. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Urology. 2011 Mar;77(3):768; author reply 768-9 [21377027.001]
  • (PMID = 19896175.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Tunici P, Yu JS: Pituitary adenoma stem cells. Methods Mol Biol; 2009;568:195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary adenoma stem cells.
  • Reports have been published on the identification of tumor cells with stem cells characteristics in different types of tumors (acute myelogenic leukemia, breast cancer, prostate cancer, bone sarcomas, liver cancer, and melanomas).
  • More recently we have isolated tumor stem-like cells also from benign tumors like pituitary adenomas.
  • Cells derived from pituitary adenomas are able to grow as floating aggregates resembling the neurospheres (typical of normal stem cells) in a medium supplemented by growth factors (EGF and bFGF).
  • In vitro tumor stem-like cells derived from a patient with a somatotroph adenoma showed high production of growth hormone and prolactin, while cells derived from the same patient but grown in presence of fetal bovine serum showed no production of hormones.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582428.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin
  •  go-up   go-down


48. Netto GJ, Epstein JI: Benign Mimickers of Prostate Adenocarcinoma on Needle Biopsy and Transurethral Resection. Surg Pathol Clin; 2008 Dec;1(1):1-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign Mimickers of Prostate Adenocarcinoma on Needle Biopsy and Transurethral Resection.
  • Prostate needle biopsy currently is the gold standard method for the diagnosis, management, and prognosis of prostate cancer.
  • Obtaining an accurate diagnosis is crucial for pursuing proper patient management.
  • This article discusses histologic mimickers of prostate carcinoma highlighting microscopic features that are helpful to reach a correct diagnosis and emphasizing potential diagnostic pitfalls.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier Inc. All rights reserved.
  • (PMID = 26837901.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adenosis / Atrophy / Basal cell hyperplasia / Clear cell cribriform hyperplasia / Mimickers of prostate cancer / Nephrogenic adenoma / Paraganglia / Prostatitis / Radiation atypia / Xanthoma
  •  go-up   go-down


49. Lopatkin NA, Maksimov VA, Khodyreva LA, Davydova EN: [Optimisation of early diagnosis of prostatic diseases in megapolis setting]. Urologiia; 2009 Sep-Oct;(5):50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optimisation of early diagnosis of prostatic diseases in megapolis setting].
  • One of the aims in the strategy of Moscow health service is perfection of early diagnosis of urological diseases.
  • The number of ultrasonographies and transrectal ultrasonic investigations of the prostate rose from 21650 (2002) to 128890 (2007), the number of polyfocal biopsies--from 2165 (2002) to 12219 (2007).
  • The rate of detection of prostatic diseases increased from 1146 cases per 100000 adult male population (1999) to 2097 (2007).
  • Chronic prostatitis was registered in 17.8%, prostatic adenoma in 29.6% examinees, new cases of prostatic cancer were detected in 0.86% examinees.
  • Standard prostatic cancer morbidity rose from 30.4 to 47.0 per 100000 male population.
  • Percentage of early detected prostatic cancer increased from 42.9% in 2000 to 62% in 2007, detection of prostatic cancer stage III-IV reduced from 27.3% in 2000 to 16.6% in 2007.
  • Thus, new prophylactic measures improved efficacy of outpatient urological service, raised rate of detection of chronic prostatitis, prostatic adenoma, prostatic cancer
  • [MeSH-major] Prostatic Diseases / diagnosis. Urban Population
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Humans. Male. Middle Aged. Moscow / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213912.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


50. Cabello Benavente R, Jara Rascón J, Monzó JI, López Díez I, Subirá Ríos D, Lledó García E, Herranz Amo F, Hernández Fernández C: [Volume determinations of the whole prostate and of the adenoma by transrectal ultrasound: correlation with surgical specimen]. Actas Urol Esp; 2006 Feb;30(2):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Volume determinations of the whole prostate and of the adenoma by transrectal ultrasound: correlation with surgical specimen].
  • [Transliterated title] Correlación ecográfico-anatómica de la medición del volumen prostático total y de la zona transicional mediante ecografía transrectal.
  • OBJECTIVE: We evaluated whether preoperative transrecta ultrasound (TRUS) mesaurements of the transition zone (TZ) and total prostate volumen predict real prostatic weight.
  • MATERIAL AND METHODS: We compare estimated TRUS volumes with surgical specimen weight, in surgically treated patients with localized prostate cancer (group A, n = 33) or benign prostatic hyperplasia (group B, n = 37).
  • Both measurements were compared with surgical specimen weight, assuming 1 as specific prostate weight.
  • RESULTS: Group A: mean prostate measured volume was 38.6 cc. (SD 22.7), mean RP specimen weight was 54,2 g (SD 27.2) (p = 0.001).
  • Total estimated prostate volume underestimated prostatectomy specimen weight by 29%.
  • In order to adequate the estimated volume to the specimen weight, we calculated the formula: estimated prostate weight = 0.95 x prostatic measured volume + 17,657 (p = 0.005).
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / ultrasonography. Prostatic Neoplasms / pathology. Prostatic Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700208.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


51. Boroian RR: [Basic fibroblast growth factor as a prognostic factor of medication efficacy by meanes of prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):49-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basic fibroblast growth factor as a prognostic factor of medication efficacy by meanes of prostatic adenoma].
  • To determine prognostic factors of lower urinary tract symptoms progression because of prostatic adenoma (PA), we studied content of the basic fibroblast growth factor (bFGF) in blood serum of patients with PA in enzyme immunoassay.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Enzyme Inhibitors / administration & dosage. Fibroblast Growth Factor 2 / blood. Finasteride / administration & dosage. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248600.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 0 / Sulfonamides; 103107-01-3 / Fibroblast Growth Factor 2; 57GNO57U7G / Finasteride; G3P28OML5I / tamsulosin
  •  go-up   go-down


52. Traore CB, Kamate B, Toure ML, Diarra T, Bayo S: [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases]. Mali Med; 2006;21(4):32-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases].
  • [Transliterated title] Aspects anatomopathologiques, cliniques et radiologiques des tumeurs benignes de la prostate au Mali, a propos de 759 cas.
  • The benign prostate tumours are dominated by prostatic adenomyoma.
  • The objective of this work is to describe the anatomo-pathological, clinical and radiological aspects of benign prostate tumours in Mali.
  • It has involved 759 patients who had histological confirmed prostate adenoma in the Department of Urology in Point G University Hospital.
  • The patients were classified according to age, the clinical exam, the rate of prostate specific antigen (PSA), the sonogram, the macro and microscopic exam.
  • The apical part of the prostate is the area mostly involved.
  • "The night pollakiuria" was the primarily clinical sign in all patients; the prostate specific antigen (PSA) is high among more than 80%.
  • [MeSH-major] Adenomyoma / pathology. Adenomyoma / radiography. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiography. Urology Department, Hospital / statistics & numerical data
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy. Hospitals, University. Humans. Incidence. Male. Mali / epidemiology. Middle Aged. Prostate-Specific Antigen / blood. Retrospective Studies. Urination Disorders / etiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437843.001).
  • [ISSN] 0464-7874
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mali
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


53. Reich O: Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas &gt;80ml: 12-mo results of a randomized prospective study. Eur Urol; 2008 Aug;54(2):436-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur Urol. 2008 Aug;54(2):427-37 [18069117.001]
  • (PMID = 18069121.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  •  go-up   go-down


54. Hiraoka Y, Shimizu Y, Iwamoto K, Takahashi H, Abe H: Trial of complete detachment of the whole prostate lobes in benign prostate hyperplasia by transurethral enucleation of the prostate. Urol Int; 2007;79(1):50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trial of complete detachment of the whole prostate lobes in benign prostate hyperplasia by transurethral enucleation of the prostate.
  • INTRODUCTION: We tried a complete detachment of the whole prostate lobes for benign prostate hyperplasia (BPH) by transurethral enucleation of the prostate (TUE).
  • MATERIALS AND METHODS: For 46 BPH cases the whole prostate lobes were detached from the surgical capsule completely by a prostate-detaching blade and resectoscope beak, and dropped into the bladder.
  • The detached prostate lobes were removed by a soft tissue morcellator.
  • The preoperative total prostate and adenoma volume by transabdominal ultrasound measurement (TAUS) were 47.75 +/- 25.63 and 27.8 +/- 17.33 ml.
  • RESULTS: In all 46 BPH cases, the whole prostate lobes could be detached completely without a perforation.
  • Postoperative prostate volume and PSA were decreased to 9.56 ml and 0.8 ng/ml with complete removal of an adenoma.
  • CONCLUSIONS: TUDP could achieve complete removal of even a large adenoma without perforation, transurethral resection syndromes and blood transfusion safety.
  • [MeSH-major] Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery


55. Goodman M, Bostick RM, Gross M, Thyagarajan B, Dash C, Flanders WD: Combined measure of pro- and anti-oxidant exposures in relation to prostate cancer and colorectal adenoma risk: an update. Ann Epidemiol; 2010 Dec;20(12):955-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined measure of pro- and anti-oxidant exposures in relation to prostate cancer and colorectal adenoma risk: an update.
  • PURPOSE: We previously proposed an oxidative balance score (OBS) and illustrated its practical application by using data from previously completed case-control studies of two neoplasms - sporadic colorectal adenoma and prostate cancer.
  • When the OBS was divided into three approximately equal intervals, a comparison of the lowest to highest category showed similar adjusted ORs (95% CIs) of 0.34 (0.13-0.88) and 0.34 (0.14-0.86) for colorectal adenoma and prostate cancer, respectively.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Mol Carcinog. 2000 Jan;27(1):18-23 [10642433.001]
  • [Cites] Cancer Lett. 2009 Sep 18;282(2):125-36 [19185987.001]
  • [Cites] Curr Med Chem. 2001 Jun;8(7):773-96 [11375749.001]
  • [Cites] J Nutr. 2002 Apr;132(4):756-61 [11925473.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1279-84 [12433703.001]
  • [Cites] J Nutr. 2003 Mar;133 Suppl 3:875S-880S [12612173.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):983-92 [15128611.001]
  • [Cites] Cancer Causes Control. 2004 Jun;15(5):493-501 [15286469.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):9-16 [9511847.001]
  • [Cites] Dig Dis. 1998 May-Jun;16(3):152-8 [9618134.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):325-30 [10453275.001]
  • [Cites] Ann Epidemiol. 2007 May;17(5):394-9 [17462547.001]
  • [Cites] Ann Epidemiol. 2007 Nov;17(11):930; author reply 931 [17855113.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1051-64 [18543072.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1271-9 [11142411.001]
  • (PMID = 21074110.001).
  • [ISSN] 1873-2585
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116795-03; United States / NCI NIH HHS / CA / R01 CA116795; United States / NCI NIH HHS / CA / R01 CA116795-01; United States / NCI NIH HHS / CA / R01 CA116795-03
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS242540; NLM/ PMC3008422
  •  go-up   go-down


56. Danilov VV, Vasil'chenko AV, Danilova TI, Besedin SA, Borshchenko SA, Danilov VV: [Pharmacourodynamic non-invasive studies in patients with prostatic adenoma]. Urologiia; 2010 Nov-Dec;(6):16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacourodynamic non-invasive studies in patients with prostatic adenoma].
  • After examination 47 patients with prostatic adenoma (mean age 63 years) received a course of alpha1-adenoblocker (omsulosin in a dose 0.4 mg/day).
  • Thus, long-term treatment with alpha1-adrenoblockers can be used as a pharmacourodynamic test to detect infravesical obstruction in patients with prostatic adenoma.
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Bladder Neck Obstruction / diagnosis. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21427987.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


57. Zhang X, Leav I, Revelo MP, Deka R, Medvedovic M, Jiang Z, Ho SM: Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon. PLoS Genet; 2009 Jan;5(1):e1000334
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AMACR was first found overexpressed in prostate cancer but not in benign glands and is now an established diagnostic marker for prostate cancer.
  • By using a panel of immunostained-laser-capture-microdissected clinical samples comprising the entire colon adenoma-carcinoma sequence, we show that deregulation of AMACR during colon carcinogenesis involves two nonrandom events, resulting in the mutually exclusive existence of double-deletion at CG3 and CG10 and deletion of CG12-16 in a newly identified CpG island within the core promoter of AMACR.
  • It existed in histologically normal colonic glands and tubular adenomas with low AMACR expression and was absent in villous adenomas and all CCas expressing variable levels of AMACR.
  • [MeSH-minor] Adenoma, Villous / genetics. Adenoma, Villous / metabolism. Adenoma, Villous / pathology. Base Sequence. Binding Sites. Cell Differentiation. Cell Line, Tumor. Humans. Molecular Sequence Data. Polymorphism, Genetic. Repressor Proteins / metabolism. Sequence Deletion / genetics. Transcription, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):15685-90 [10748193.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):79-92 [11438457.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Lipid Res. 2002 Mar;43(3):438-44 [11893780.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):841-8 [12213712.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1807-8; discussion 1807-8 [12229925.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):228-33 [12673556.001]
  • [Cites] J Lipid Res. 2003 May;44(5):968-77 [12611910.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):775-83 [12917210.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):792-6 [14506641.001]
  • [Cites] Cancer Detect Prev. 2003;27(6):422-6 [14642549.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):47-53 [14689581.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):787-93 [14982833.001]
  • [Cites] Histopathology. 2004 Sep;45(3):218-25 [15330799.001]
  • [Cites] Cell. 1980 Oct;21(3):653-68 [6985477.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Int J Cancer. 1992 May 28;51(3):386-9 [1592529.001]
  • [Cites] Genome Res. 2007 Jun;17(6):807-17 [17567999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1536-42 [17684125.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1487-97 [17680641.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1507-13 [17683075.001]
  • [Cites] Oncogene. 2007 Nov 15;26(52):7346-54 [17525739.001]
  • [Cites] Environ Health Perspect. 2008 Jun;116(6):769-76 [18560533.001]
  • [Cites] Genome Res. 2008 Nov;18(11):1763-77 [18836037.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;301:259-81 [16570852.001]
  • [Cites] Am J Hum Genet. 1992 Dec;51(6):1325-33 [1463014.001]
  • [Cites] Hum Mol Genet. 1997 Jun;6(6):881-5 [9175734.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1283-7 [10098773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2970-4 [15710887.001]
  • [Cites] Mol Cancer Res. 2005 Feb;3(2):110-8 [15755877.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):316-23 [15599942.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] Bioinformatics. 2005 Jul 1;21(13):2933-42 [15860560.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):252-5 [16082251.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Sep;20(9):1410-5 [16105129.001]
  • [Cites] Clin Transl Oncol. 2006 Jun;8(6):391-8 [16790391.001]
  • [Cites] Atherosclerosis. 2006 Sep;188(1):43-50 [16289551.001]
  • [Cites] Cancer Causes Control. 2007 Feb;18(1):41-50 [17315319.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):850-6 [17442371.001]
  • [Cites] J Med Chem. 2007 May 31;50(11):2700-7 [17477519.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):175-80 [17525630.001]
  • (PMID = 19148275.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112532; United States / NCI NIH HHS / CA / R01 CA112532; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NCI NIH HHS / CA / R01 CA015776; United States / NCI NIH HHS / CA / CA015776; United States / NCI NIH HHS / CA / R01 CA062269; United States / NCI NIH HHS / CA / CA062269
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / ZNF202 protein, human; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC2613032
  •  go-up   go-down


58. Hautmann RE, Stein JP: Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am; 2005 May;32(2):177-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction.
  • The modified procedure includes cystectomy with sparing of prostate, vasa deferens, seminal vesicles, and resection of a prostatic adenoma to avoid bladder outlet obstruction and bladder reconstruction with an orthotopic reservoir.
  • Furthermore, surgeons considering procedures that preserve a portion of the prostatic urethra, the prostatic capsule, or the entire prostate should recognize a 6% risk of significant prostatic cancer in any residual tissue, and the potential risk of urethral tumor involvement with TCC.
  • [MeSH-minor] Humans. Male. Patient Selection. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Seminal Vesicles. Treatment Outcome


59. Bapat S, Umranikar S, Satav V, Bapat A, Joshi A, Ranade G: Comparison of fluid absorption during transurethral resection of prostate and Holmium-Yag laser enucleation of benign adenoma of prostate using breath ethanol concentration. Indian J Urol; 2007 Apr;23(2):126-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of fluid absorption during transurethral resection of prostate and Holmium-Yag laser enucleation of benign adenoma of prostate using breath ethanol concentration.
  • OBJECTIVE: We conducted a study to detect, quantify and compare irrigation fluid absorption in transurethral resection of the prostate (TURP) and Holmium laser enucleation of the prostate (HoLEP), using BEC.
  • MATERIALS AND METHODS: The study included 50 patients of lower urinary tract symptoms, secondary to benign enlargement of prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1989 Feb;141(2):243-7 [2643719.001]
  • [Cites] Acta Anaesthesiol Scand. 1989 Feb;33(2):146-51 [2922983.001]
  • [Cites] Scand J Urol Nephrol. 1986;20(4):245-51 [3101171.001]
  • [Cites] Int Urol Nephrol. 1987;19(2):165-9 [3667130.001]
  • [Cites] Scand J Urol Nephrol. 1986;20(1):19-26 [3704567.001]
  • [Cites] J Urol. 1969 Dec;102(6):714-9 [4906205.001]
  • [Cites] Br J Urol. 1980 Dec;52(6):526-8 [6161668.001]
  • [Cites] Eur Urol. 1984;10(3):183-6 [6723737.001]
  • [Cites] Lasers Surg Med. 1994;14(3):258-68 [8208052.001]
  • [Cites] Lasers Surg Med. 1996;18(3):278-93 [8778524.001]
  • [Cites] J Endourol. 1998 Jun;12(3):279-82 [9658303.001]
  • [Cites] J Endourol. 1999 Apr;13(3):181-90 [10360498.001]
  • [Cites] J Urol. 1999 Nov;162(5):1640-4 [10524887.001]
  • [Cites] BJU Int. 2000 Jul;86(1):43-6 [10886081.001]
  • [Cites] J Urol. 1958 Mar;79(3):490-9 [13514908.001]
  • [Cites] Surg Clin North Am. 1992 Jun;72(3):531-58 [1589829.001]
  • [Cites] Br J Urol. 1991 Oct;68(4):390-3 [1933159.001]
  • [Cites] J Urol. 1947 Aug;58(2):125-31 [20256856.001]
  • [Cites] Scand J Urol Nephrol. 1986;20(1):9-17 [2422743.001]
  • (PMID = 19675787.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2721519
  • [Keywords] NOTNLM ; Breath ethanol concentration / Holmium laser enucleation of the prostate / fluid absorption / transurethral resection of the prostate
  •  go-up   go-down


60. Park C, Yoo JH, Kim HJ, Lim CY, Kim JW, Lee SY, Kim JH, Jang JI, Park HM: Cyclosporine treatment of perianal gland adenoma concurrent with benign prostatic hyperplasia in a dog. Can Vet J; 2010 Nov;51(11):1279-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclosporine treatment of perianal gland adenoma concurrent with benign prostatic hyperplasia in a dog.
  • The nodules were diagnosed as perianal gland adenoma based on histopathologic examination.
  • [MeSH-major] Adenoma / veterinary. Anal Gland Neoplasms / drug therapy. Cyclosporine / therapeutic use. Dog Diseases / drug therapy. Immunosuppressive Agents / therapeutic use
  • [MeSH-minor] Animals. Dogs. Hyperplasia / drug therapy. Hyperplasia / veterinary. Male. Prostate / drug effects. Prostate / pathology. Prostatic Diseases / drug therapy. Prostatic Diseases / veterinary. Treatment Outcome

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2001 Mar 5;193(5):607-20 [11238591.001]
  • [Cites] J Neurochem. 1997 Mar;68(3):1142-9 [9048760.001]
  • [Cites] Vet Dermatol. 2002 Apr;13(2):77-87 [11972891.001]
  • [Cites] J Am Vet Med Assoc. 2002 Aug 1;221(3):370-7 [12164533.001]
  • [Cites] J Am Vet Med Assoc. 2002 Apr 1;220(7):1009-16 [12420778.001]
  • [Cites] Vet Dermatol. 2003 Feb;14(1):1-9 [12603680.001]
  • [Cites] Vet Dermatol. 2003 Feb;14(1):11-22 [12603681.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Jun;284(6):C1593-603 [12734112.001]
  • [Cites] J Small Anim Pract. 2004 May;45(5):238-43 [15163050.001]
  • [Cites] Vet Rec. 1975 Dec 13;97(24):464-7 [173072.001]
  • [Cites] Cancer Res. 1977 Jul;37(7 Pt 1):2068-71 [861936.001]
  • [Cites] Aust Vet J. 2004 Nov;82(11):681-5 [15977612.001]
  • [Cites] J Am Vet Med Assoc. 2005 Jun 1;226(11):1855-63 [15934253.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Mar;46(3):782-90 [15728531.001]
  • [Cites] J Neurol. 1999 May;246(5):339-46 [10399863.001]
  • [Cites] Transplant Proc. 1998 Aug;30(5):2167-70 [9723430.001]
  • [Cites] Vet Surg. 1998 Jan-Feb;27(1):64-8 [9449179.001]
  • [Cites] J Am Vet Med Assoc. 1997 Nov 15;211(10):1249-53 [9373359.001]
  • [Cites] J Urol. 1987 Oct;138(4 Pt 2):991-5 [3656581.001]
  • [Cites] Can Vet J. 1997 Jan;38(1):39-41 [8993784.001]
  • [Cites] J Am Vet Med Assoc. 1996 Feb 15;208(4):517-9 [8603899.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2689-98 [7545467.001]
  • [Cites] Mol Cell Endocrinol. 1994 Feb;99(1):21-4 [8187957.001]
  • [Cites] Transplantation. 1992 Jan;53(1):190-5 [1310171.001]
  • [Cites] Am J Vet Res. 1988 Oct;49(10):1742-6 [3189991.001]
  • [Cites] Endocrinology. 1988 Aug;123(2):1069-74 [3396498.001]
  • [Cites] Res Vet Sci. 2006 Oct;81(2):231-6 [16427103.001]
  • [Cites] Vet Rec. 2001 May 26;148(21):662-3 [11400987.001]
  • (PMID = 21286331.001).
  • [ISSN] 0008-5286
  • [Journal-full-title] The Canadian veterinary journal = La revue vétérinaire canadienne
  • [ISO-abbreviation] Can. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  • [Other-IDs] NLM/ PMC2957039
  •  go-up   go-down


61. Danilov VV, Elisseva EV, Vasil'chenko AV: [Tadenan treatment of prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):68, 70-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tadenan treatment of prostatic adenoma].
  • Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months.
  • [MeSH-major] Plant Extracts / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526878.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Fatty Alcohols; 0 / Plant Extracts; 0 / Tadenan
  •  go-up   go-down


62. Pandak N, Tomić-Paradzik M, Krizanović B, Fornet-Sapcevski J: [The importance of Streptococcus bovis systemic infections]. Lijec Vjesn; 2006 Jul-Aug;128(7-8):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These infections are frequently connected with malignant, potentially malignant, or benign colorectal neoplasia.
  • He was an older man, who had undergone prostatectomy due prostatic adenoma several years before.
  • Histologically, in both cases, those were benign neoplasia.
  • [MeSH-minor] Adult. Aged. Bacteremia / diagnosis. Bacteremia / therapy. Humans. Male. Meningitis, Bacterial / diagnosis. Meningitis, Bacterial / microbiology. Meningitis, Bacterial / therapy

  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17087134.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


63. Bartoletti R, Cai T, Tinacci G, Longo I, Ricci A, Massaro MP, Tosoratti N, Zini E, Pinzi N: Transperineal microwave thermoablation in patients with obstructive benign prostatic hyperplasia: a phase I clinical study with a new mini-choked microwave applicator. J Endourol; 2008 Jul;22(7):1509-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transperineal microwave thermoablation in patients with obstructive benign prostatic hyperplasia: a phase I clinical study with a new mini-choked microwave applicator.
  • PURPOSE: To evaluate the tolerability and safety of a newly designed probe for trans-perineal microwave thermoablation (TPMT) of the prostate in patients with benign prostatic hyperplasia (BPH), and the in vivo microwave effects on prostatic tissue.
  • Then the International Index of Erectile Function (IIEF-5) and International Prostate Symptom Score (IPSS) questionnaires were administered to each patient at baseline and 1 month after prostatectomy in order to evaluate sexual and urinary function, respectively.
  • The prostatic adenomas were then evaluated by a pathologist.
  • Quasi-spheroid lesions with a well-defined area of complete coagulative necrosis were documented in all removed adenomas 7, 15, and 30 days after TMPT.

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613779.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Hojgaard M, Mikines KJ: Ureteral injuries during photoselective vaporization of the prostate. Scand J Urol Nephrol; 2010 Sep;44(4):265-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ureteral injuries during photoselective vaporization of the prostate.
  • Photoselective vaporization of the prostate is a relatively new surgical modality for male lower urinary tract symptoms.
  • The method has a risk of tissue damage if laser pulses miss the prostatic adenoma and travel through the irrigation fluid in the bladder.
  • Five cases of damage to the ureteral orifices are described, with hidden orifices, intravesical prostatic adenomas and prior prostatectomy as risk factors for laser-related injuries to ureteral orifices.
  • [MeSH-major] Laser Therapy / adverse effects. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Ureter / injuries

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201751.001).
  • [ISSN] 1651-2065
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Shkol'nikov ME, Iakushkin VR: [Diagnosis and treatment of nocturia in patients with prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of nocturia in patients with prostatic adenoma].
  • [MeSH-major] Nocturia / diagnosis. Nocturia / therapy. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248603.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 63
  •  go-up   go-down


66. Gorilkovskiĭ LM, Zingerenko MB: [Efficacy and safety of tulosine in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):60, 62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of tulosine in patients with prostatic adenoma].
  • The study of tulosine (tamsulosine) efficacy and safety was made in 92 patients with lower urinary tract symptoms (LUTS) due to prostatic adenoma (PA).
  • Ultrasound investigation found no significant changes in the adenoma size.
  • Thus, tulosine is a safe and effective drug for treatment of prostatic adenoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage. Sulfonamides / adverse effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526876.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


67. Trapeznikova MF, Dutov VV, Dolgovq AG, Urenkov SB: [Prostamol-Uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis]. Urologiia; 2008 Sep-Oct;(5):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostamol-Uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis].
  • We studied efficacy and safety of prostamol-Uno (PU) monotherapy in patients with prostatic adenoma (PA) comorbid with chronic abacterial prostatitis (CAP) in a clinical open trial including 45-year-old males aged over 45 years with PA comorbid with CAP, having irritative and obstructive symptoms by IPSS above 8 points and duration 6 months or longer, by NIH-CPSI above 10 points and duration 3 months or longer.
  • The patients had Qmax from 5 to 15 ml/s, urine volume 100-350 ml, residual urine volume under 150 ml, prostate size more than 25 cm3, PSA level under 4 ng/ml and no bacterial growth in the third urine portion seeding and/or prostatic secretion.
  • The effect was assessed by the disease history, complaints, digital rectal examination of the prostate, the disease symptoms by IPSS, quality of life (QoL), NIH-CPSI, bacteriological tests of the urine and prostatic secretion, urinalysis, Nechiporenko test in 3 urine portions.
  • Uroflowmetry, ultrasonic investigation of the urinary bladder and prostate, transrectal energy dopplerography of the prostate, PSA assay in the blood serum were made in all the patients.
  • Spectral doppler examination detected improvement in prostatic blood flow after PU treatment in 16 (53.3%) patients.
  • Thus, PU effectively reduces irritative and obstructive symptoms typical for prostatic adenoma in combination with CAP.
  • [MeSH-major] Plant Extracts / administration & dosage. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy
  • [MeSH-minor] Blood Pressure / drug effects. Chronic Disease. Electrocardiography. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Quality of Life. Urination / drug effects


68. Tinmouth WW, Habib E, Kim SC, Kuo RL, Paterson RF, Terry CL, Elhilali M, Lingeman JE: Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? J Endourol; 2005 Jun;19(5):550-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection?
  • BACKGROUND AND PURPOSE: Holmium laser enucleation of the prostate (HoLEP) is a well-established technique for the treatment of benign prostatic hyperplasia (BPH).
  • To date, changes in serum prostate specific antigen (PSA) after HoLEP have not been published.
  • Change in PSA as a function of the weight of prostate resected and the relation of preoperative TRUS volume to PSA was determined.
  • RESULTS: The average weight of adenoma resected was 49.8 g (range 5-300 g) in the McGill group and 90.4 g (range 7.9-312 g) in the Methodist Hospital group.
  • Log transformed preoperative PSA correlated well with TRUS volume (r = 0.45), as did the weight of adenoma resected with absolute change in PSA (r = 0.38).
  • CONCLUSION: The HoLEP procedure produces a significant diminution in PSA that correlates well with the weight of adenoma resected.
  • Measurement of PSA may be a useful tool for the objective assessment of ablative therapies for BPH, as the reduction in PSA corresponds well with the amount of adenoma removed.


69. Barrier F, de La Guerenne A, Semjen E, Wierre L, Horrent S, Decaudin B, Resibois JP, Weillaert MP, Azar R, Odou P: [Spontaneously acquired haemophilia: report of a patient with prostatic adenoma]. Ann Biol Clin (Paris); 2006 Jul-Aug;64(4):347-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spontaneously acquired haemophilia: report of a patient with prostatic adenoma].
  • [Transliterated title] Hémophilie A acquise secondaire à un adénome prostatique.
  • Two diagnosis were suspected: a coagulation factor defect, or the presence of a lupus anticoagulant or of anti-factor antibodies.
  • A prostatic adenocarcinoma was suspected: a 5 cm prostatic tumour was found and the PSA level was 113 ng/mL.
  • The patient's disease was identified as a spontaneously acquired haemophilia A associated with prostatic adenocarcinoma.
  • [MeSH-major] Adenoma / complications. Hemophilia A / etiology. Prostatic Neoplasms / blood. Prostatic Neoplasms / complications
  • [MeSH-minor] Aged, 80 and over. Anemia / etiology. Diagnosis, Differential. Factor VIII / analysis. Hematoma. Humans. Male. Prostate-Specific Antigen / blood. Triazines

  • MedlinePlus Health Information. consumer health - Hemophilia.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16829479.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Triazines; 55824-91-4 / 4-azido-7-phenylpyrazolo-(1,5a)-1,3,5-triazine; 9001-27-8 / Factor VIII; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


70. Lee SW, Cho JM, Kang JY, Yoo TK: Clinical and urodynamic significance of morphological differences in intravesical prostatic protrusion. Korean J Urol; 2010 Oct;51(10):694-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and urodynamic significance of morphological differences in intravesical prostatic protrusion.
  • PURPOSE: The objectives of this study were to evaluate whether morphologic differences correlated with urodynamic and clinical characteristics in patients with benign prostatic hyperplasia (BPH) with intravesical prostatic protrusion (IPP) of trilobar or bilobar adenoma.
  • They underwent preoperative urodynamic studies, the International Prostate Symptom Score (IPSS)/quality of life (QoL), maximal flow rate (Qmax), post-voiding residual urine volume (PVR), transrectal ultrasonography (TRUS), and serum prostate-specific antigen (PSA) measurement.
  • The patients were classified into 2 groups (the trilobar and bilobar adenoma groups) on the basis of video findings during the TUR operation.
  • RESULTS: The trilobar and bilobar adenoma groups consisted of 37 patients and 35 patients, respectively.
  • The Mean±SD IPP, prostate volume (PV), and transition zone volume of the trilobar and bilobar adenoma groups were 11.8±5.2 mm and 9.0±3.8 mm (p=0.014), 81.1±25.8 g and 59.3±22.5 g (p<0.001), and 49.6±20.6 g and 34.8±19.4 g (p=0.003), respectively.
  • The PV, BOOI, and BCI were significantly smaller in the bilobar adenoma group than in the trilobar adenoma group.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21031089.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2963782
  • [Keywords] NOTNLM ; Prostatic hyperplasia / Ultrasonography / Urodynamics
  •  go-up   go-down


71. Bastide C, Rambeaud JJ, Bach AM, Russo P: Metanephric adenoma of the kidney: clinical and radiological study of nine cases. BJU Int; 2009 Jun;103(11):1544-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metanephric adenoma of the kidney: clinical and radiological study of nine cases.
  • OBJECTIVE To analyse the clinical and radiological features of metanephric adenoma (MA, a rare benign renal tumour) in nine patients, and to review previous reports.
  • CONCLUSIONS Renal MA is a benign tumour occurring mainly in young and middle-aged women.
  • Based on a combination of clinical and imaging features, it might be possible to suspect the diagnosis of MA and propose a preoperative diagnostic biopsy, a partial nephrectomy or active surveillance.
  • [MeSH-major] Adenoma / pathology. Kidney Neoplasms / pathology. Nephrectomy / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220269.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Likhin FA, Bartnovskiĭ AE, Vdovichenko KK, Abramov AA, Belokhvostov AS: [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma]. Urologiia; 2005 Jul-Aug;(4):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma].
  • The study was made of possibilities of methyl-specific PCR-test of glutathione-S-transferase P1 (GSTP1) gene in differential diagnosis of prostatic cancer: sensitivity of the test, comparison of reagents of Russian and foreign production.
  • Blood plasm and cellur urinary precipitate DNA was investigated in patients with prostatic adenocarcinoma.
  • The results show that the above test with domestic reagents is rather perspective for differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. DNA, Neoplasm / analysis. Polymerase Chain Reaction / methods. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] DNA / blood. DNA / metabolism. DNA / urine. DNA Methylation. Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158738.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


73. Rehman J, Khan SA, Sukkarieh T, Chughtai B, Waltzer WC: Extraperitoneal laparoscopic prostatectomy (adenomectomy) for obstructing benign prostatic hyperplasia: transvesical and transcapsular (Millin) techniques. J Endourol; 2005 May;19(4):491-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraperitoneal laparoscopic prostatectomy (adenomectomy) for obstructing benign prostatic hyperplasia: transvesical and transcapsular (Millin) techniques.
  • PURPOSE: We describe extraperitoneal laparoscopic resection of large prostatic adenomas (<100 g) as an alternative to open simple prostatectomy by both the transcapsular or Millin and the transvesical approaches.
  • PATIENTS AND METHODS: We have performed more than 20 laparoscopic prostatectomies (adenomectomies) for benign prostatic hyperplasia (BPH) for glands >100 g.
  • Using an extraperitoneal approach, enucleation of the obstructing prostatic lobes was performed with the aid of a Harmonic Scalpel and laparoscopic claw forceps.
  • The adenoma removed was approximately 138 g in the first case and 102 g in the second case.


74. Shaplygin LV, Sivakov AA: [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis]. Urologiia; 2007 May-Jun;(3):35-7, 39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis].
  • A conservative therapy with cernilton was given to 72 patients with chronic prostatitis and prostatic adenoma of stage I-II.
  • Detailed urologic examination before the treatment and after it demonstrates that cernilton is effective, safe and well tolerated medicine for prostatic adenoma and chronic prostatitis.
  • Cernilton is recommended for wider use in the treatment of patients with prostatic adenoma and chronic prostatitis.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722618.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Plant Extracts; 8054-43-1 / cernilton
  •  go-up   go-down


75. Mazo EB, Krivoborodov GG, Shkol'nikov ME, Efremov NS: [Botulinic toxin of type A in the treatment of prostatic adenoma and cancer]. Urologiia; 2008 Jul-Aug;(4):63-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Botulinic toxin of type A in the treatment of prostatic adenoma and cancer].
  • [MeSH-major] Botulinum Toxins, Type A / therapeutic use. Neuromuscular Agents / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Botox.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058365.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  • [Number-of-references] 37
  •  go-up   go-down


76. Maksimov IB, Sergienko NF, Shchekochikhin AV, Deviatov AS, Baglaĭ GV: [The 20th anniversary of Urological Center of Main Military Clinical Hospital named after N. N. Burdenko]. Voen Med Zh; 2009 Sep;330(9):38-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent diseases--adenoma of prostate, malignant swelling and benign tumour of urological organs, urolithiasis, traumatic damages of urological organs.
  • [MeSH-minor] History, 20th Century. History, 21st Century. Humans. Male. Moscow. Prostatectomy / history. Prostatectomy / methods. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / history. Prostatic Hyperplasia / surgery. Urologic Diseases / diagnosis. Urologic Diseases / history. Urologic Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20020614.001).
  • [ISSN] 0026-9050
  • [Journal-full-title] Voenno-medit︠s︡inskiĭ zhurnal
  • [ISO-abbreviation] Voen Med Zh
  • [Language] rus
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


77. Tkachuk VN, Al'-Shukri SKh, Tkachuk IN, Mosoian MS: [Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers]. Urologiia; 2009 Nov-Dec;(6):25-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers].
  • Pharmacotherapy of prostatic adenoma is based in present-day practice primarily on two basic groups of medicines--inhibitors of 5alpha-reductase and blockers of alphal-adrenoreceptors.
  • Our trial included 98 patients with prostatic adenoma aged 59-79 years given combined treatment with finasteride (inhibitor of 5alpha-reductase) made in Hungary (prosteride, Gedeon Richter) and an uroselective blocker of alpha1-adrenoreceptors sonisin (Gedeon Richter, Hungary).
  • After 12-month combined treatment symptoms of the disease reduced by IPSS from 17.9 +/- 1.8 to 3.9 +/- 0.9 points, Qmax rose from 8.8 +/- 0.3 to 14.6 +/- 0.3, residual urine volume diminished from 91.7 +/- 8.5 to 31.7 +/- 4.4, the size of the prostate reduced from 72.4 +/- 2.9 to 50.6 +/- 3.7, quality of life improved 2-fold.
  • Combined administration of finasteride (prosteride) and alpha1-adrenoblocker tamsulosine (sonisine) meet three principles of pharmacotherapy of prostatic adenoma: prevents progression of the disease and surgical treatment, relieves symptoms and improves quality of life.
  • [MeSH-major] 5-alpha Reductase Inhibitors. Adrenergic alpha-Antagonists / administration & dosage. Finasteride / administration & dosage. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169718.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 0 / Sulfonamides; 57GNO57U7G / Finasteride; G3P28OML5I / tamsulosin
  •  go-up   go-down


78. Vinarov AZ, Aliaev IuG, Apolikhin OI, Mazo EB, Darenkov SP, Demidko IuL, Lokshin KL, Medvedev AA, Permiakova OV, Spivak LG, Shkol'nikov ME: [Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression]. Urologiia; 2010 Nov-Dec;(6):3-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression].
  • PU was given in a single daily dose 320 mg for 36 months to 50 patients with initial symptoms of prostatic adenoma (PA) in comparison with 50 matched controls.
  • Administration of PU significantly increased urinary flow rate though in the controls urinary flow rate decreased, size of the prostate diminished and increased, respectively.
  • [MeSH-major] Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Disease Progression. Humans. Male. Middle Aged. Organ Size. Prostate / drug effects. Prostate / ultrasonography. Prostate-Specific Antigen / blood. Quality of Life. Risk. Treatment Outcome. Urinary Bladder / physiopathology. Urinary Bladder / ultrasonography. Urinary Retention / etiology. Urinary Retention / physiopathology. Urinary Retention / prevention & control. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21433319.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Prostamol-Uno; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


79. Tarasov NI, Izmaĭlov RI: [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride]. Urologiia; 2009 Sep-Oct;(5):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride].
  • Combined treatment with doxasozine and finasteride was performed for 7.26 months in 38 patients with large-size prostatic adenoma (89.54 +/- 11.64 cm3).
  • The control group (28 patients with large prostatic adenoma) received surgical treatment alone.
  • Thus, combined treatment with doxasozine and finasteride can be the first-line treatment in patients with large prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Doxazosin / administration & dosage. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Prostatectomy. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209869.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down


80. Grigor'ev ME, Konorev VA: [Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?]. Urologiia; 2007 Nov-Dec;(6):90, 92-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?].
  • [MeSH-major] 5-alpha Reductase Inhibitors. Azasteroids / therapeutic use. Enzyme Inhibitors / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652016.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Azasteroids; 0 / Enzyme Inhibitors; EC 1.3.99.5 / 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; EC 1.3.99.5 / steroid-5alpha-reductase type 1; EC 1.3.99.5 / steroid-5alpha-reductase type 2; O0J6XJN02I / Dutasteride
  • [Number-of-references] 46
  •  go-up   go-down


81. Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT: Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Urology; 2009 Jul;74(1):177-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
  • OBJECTIVES: To determine whether prostate-specific antigen (PSA) values can distinguish those with prostate cancer (CaP) from those with histologic benign prostatic hyperplasia (BPH) only after surgical intervention.
  • Prostatic adenoma inevitably remains after BPH surgery; therefore, patients remain at risk of developing CaP.
  • METHODS: We performed a review of patients who had undergone transurethral resection of the prostate (TURP; n = 343), holmium laser resection of the prostate (HoLRP; n = 54), or open prostatectomy (OP; n = 68).
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis


82. Avdoshin VP, Andriukhin MI, Mikhaĭlikov TG, Ol'shanskaia EV, Khunov AZ: [Tulozin in combined treatment of patients with acute urinary retention]. Urologiia; 2009 Jul-Aug;(4):11-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is much evidence that tulozin promotes recovery of spontaneous urination, Qmax and is effective in combined treatment of patients with acute retention of urine caused by prostatic adenoma.
  • Tulozin is recommended for patients of younger age, with minimal comorbid pathology, hypotonic with orthostatic reactions, history of side effects in the treatment of other alpha-adrenoblockers, in comorbid hypertention, hypercholesterolemia, retrograde ejaculation, low potention, overactive bladder, prostatitis, after prostatic TUR, transvesical adenomectomy.
  • [MeSH-minor] Acute Disease. Adult. Age Factors. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Prostatic Hyperplasia / therapy

  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824378.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


83. Ge D, You Z: Expression of interleukin-17RC protein in normal human tissues. Int Arch Med; 2008;1(1):19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: IL-17RC expression in 51 normal human tissues and two benign tumors (i.e., lymphangioma and parathyroid adenoma) on the tissue microarrays was determined by immunohistochemical staining, using two polyclonal antibodies against IL-17RC.
  • IL-17RC protein was expressed in many cell types including the myocardial cells, vascular and lymphatic endothelial cells, glandular cells (of the adrenal, parathyroid, pituitary, thyroid, pancreas, parotid salivary, and subepidermal glands), epithelial cells (of the esophagus, stomach, intestine, anus, renal tubule, breast, cervix, Fallopian tube, epididymis, seminal vesicle, prostate, gallbladder, bronchus, lung, and skin), oocytes in the ovary, Sertoli cells in the testis, motor neurons in the spinal cord, autonomic ganglia and nerves in the intestine, skeletal muscle cells, adipocytes, articular chondrocytes, and synovial cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2078-87 [18310510.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1207-11 [18200064.001]
  • [Cites] Cytokine. 2008 Feb;41(2):92-104 [18178098.001]
  • [Cites] Cytokine. 2008 Feb;41(2):105-13 [18061473.001]
  • [Cites] Cytokine. 2008 Feb;41(2):84-91 [18039580.001]
  • [Cites] J Clin Invest. 2008 Feb;118(2):597-607 [18202747.001]
  • [Cites] Nat Immunol. 2008 Feb;9(2):124-6 [18204425.001]
  • [Cites] J Immunol. 2008 Jan 1;180(1):655-63 [18097068.001]
  • [Cites] Cytokine. 2007 Oct;40(1):35-43 [17881243.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5462-73 [17911633.001]
  • [Cites] Cytokine. 2007 Jun;38(3):157-64 [17644350.001]
  • [Cites] J Heart Lung Transplant. 2007 Jul;26(7):669-74 [17613395.001]
  • [Cites] Neoplasia. 2007 Jun;9(6):464-70 [17603628.001]
  • [Cites] Cell Res. 2007 May;17(5):435-40 [17452998.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13447-55 [17355969.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4466-72 [17372004.001]
  • [Cites] J Neuroimmunol. 2007 Feb;183(1-2):96-103 [17240458.001]
  • [Cites] J Immunol. 2007 Feb 1;178(3):1372-8 [17237384.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8542-9 [17142752.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6852-8 [17082599.001]
  • [Cites] Prostate. 2006 Sep 1;66(12):1268-74 [16688746.001]
  • [Cites] J Neurosci Res. 2006 Aug 1;84(2):379-88 [16676327.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):566-73 [16785554.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):36-9 [16785495.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1685-91 [16818675.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1287-98 [16310341.001]
  • [Cites] Cell Immunol. 2005 Oct;237(2):123-30 [16386239.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):175-83 [16397230.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):711-5 [16393951.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6177-89 [16237115.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Sep;33(3):248-53 [15901616.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):404-12 [15972674.001]
  • [Cites] J Cell Physiol. 2005 Aug;204(2):560-6 [15799031.001]
  • [Cites] Immunity. 2005 Mar;22(3):285-94 [15780986.001]
  • [Cites] J Exp Med. 2005 Jan 17;201(2):233-40 [15657292.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 21;326(3):624-31 [15596145.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8276-84 [15548695.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3698-704 [10446984.001]
  • [Cites] J Immunol. 1999 Jan 1;162(1):577-84 [9886435.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5483-6 [7499828.001]
  • [Cites] Immunity. 1995 Dec;3(6):811-21 [8777726.001]
  • [Cites] Immunity. 2004 Oct;21(4):467-76 [15485625.001]
  • [Cites] Joint Bone Spine. 2004 Mar;71(2):87-90 [15050191.001]
  • [Cites] Cell Mol Life Sci. 2004 Mar;61(5):567-79 [15004696.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1229-34 [14742870.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50273-82 [12958313.001]
  • [Cites] Br J Pharmacol. 2003 Oct;140(4):595-610 [14504135.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33232-8 [12807873.001]
  • [Cites] Prostate. 2003 Aug 1;56(3):171-82 [12772186.001]
  • [Cites] Scand J Gastroenterol. 2003 Feb;38(2):180-5 [12678335.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Apr;14(2):155-74 [12651226.001]
  • [Cites] Gut. 2003 Jan;52(1):65-70 [12477762.001]
  • [Cites] Nat Med. 2002 May;8(5):500-8 [11984595.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):4309-16 [11706037.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):170-4 [11802165.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):165-9 [11802164.001]
  • [Cites] J Immunol. 2002 Jan 15;168(2):861-8 [11777983.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):6015-20 [11698482.001]
  • [Cites] Transplant Proc. 2000 Nov;32(7):1773 [11119928.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1660-4 [11058597.001]
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):19167-76 [10749887.001]
  • [Cites] J Immunol. 2008 Aug 15;181(4):2799-805 [18684971.001]
  • [Cites] J Exp Med. 2008 May 12;205(5):1063-75 [18411338.001]
  • (PMID = 18928529.001).
  • [ISSN] 1755-7682
  • [Journal-full-title] International archives of medicine
  • [ISO-abbreviation] Int Arch Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2596096
  •  go-up   go-down


84. Rasner PI, Pushkar' DIu: [Administration of two uroselective alpha-adrenoblockers in pharmacological treatment of acute urinary retention in patients with prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Administration of two uroselective alpha-adrenoblockers in pharmacological treatment of acute urinary retention in patients with prostatic adenoma].
  • Acute urinary retention in males is often caused by infravesical obstruction due to enlargement of the prostatic gland.
  • Recently it was found that alpha-adrenoblockers promote recovery of physiological voiding in patients with benign prostatic hyperplasia.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / therapy. Quinazolines / administration & dosage. Sulfonamides / administration & dosage. Urinary Catheterization. Urinary Retention / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. ALFUZOSIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169720.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Quinazolines; 0 / Sulfonamides; 90347YTW5F / alfuzosin; G3P28OML5I / tamsulosin
  •  go-up   go-down


85. [Prostatic adenoma and overactive urinary bladder: assessment of symptoms and choice of therapy]. Urologiia; 2009 Mar-Apr;(2):78, 80-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatic adenoma and overactive urinary bladder: assessment of symptoms and choice of therapy].
  • [MeSH-major] Prostatic Hyperplasia / physiopathology. Prostatic Hyperplasia / therapy. Urinary Bladder, Overactive / physiopathology. Urinary Bladder, Overactive / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526881.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


86. Aliaev IuG, Grigorian VA, Tsarichenko DG, Lokshin KL, Kharchilava RR: [Transurethral electroresection of prostatic adenoma under transrectal ultrasonic control]. Urologiia; 2006 May-Jun;(3):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral electroresection of prostatic adenoma under transrectal ultrasonic control].
  • The aim of the study was to improve the results of transurethral prostatic resection (TUPR) by introduction of intraoperative transrectal ultrasonic investigation (TRUSI) and to determine topographic-anatomic features of the prostate, intraorgan relations of adenomatous nodes and surgical prostatic capsule on-line in TUPR.
  • A total of 64 patients with prostatic adenoma (PA) of the second degree aged 52-79 participated in the study.
  • The patients were divided into two study groups (15 patients with volume of the prostate 36.5-78.6 cm3 and 17 patients with prostate size 80-4-141.2 cm3) in which TRUSI was performed and two control groups (n = 14, size 34.9 to 79.2 cm3 and n = 18, size 81.7-130.8 cm3, respectively) who have not undergone intraoperative TRUSI.
  • Control TRUSI on day 7 after TUPR registered mean volume of the prostate to be 19.3 +/- 1.4 cm3 in group 1, 39.8 +/- 2.1 cm3 in group 2, 28.1 +/- 1.6 cm3 in group 3, 47.7 +/- 3.2 cm3 in group 4.
  • Thus, intraoperative TRUSI provides information which helps the surgeon to orient in the course of surgery and minimize the threat of perforation of the prostatic capsule; minimizes intraoperative complications and enhances efficacy of radical transurethral electroresection of prostatic hyperplasia improving long-term outcomes of the operation.
  • [MeSH-major] Intraoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatic Hyperplasia / ultrasonography. Transurethral Resection of Prostate. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889081.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


87. Takle M, Hjelle K, Beisland C: [Transvesical prostatectomy]. Tidsskr Nor Laegeforen; 2007 Feb 15;127(4):435-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mean operation time of patients with benign symptom-giving prostate enlargement was 88 min, blood loss during the operation was 917 mL and 50% of the patients received blood-transfusions during hospitalisation.
  • The median weight of enucleated prostate adenomas was 107 g and carcinoma(s) were incidentally found for 4 patients (7%).
  • [MeSH-minor] Adenoma / surgery. Aged. Aged, 80 and over. Carcinoma / surgery. Humans. Male. Middle Aged. Patient Satisfaction. Postoperative Complications / etiology. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Reoperation. Retrospective Studies. Surveys and Questionnaires. Urinary Incontinence / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304271.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


88. Trapeznikova MF, Pozdniakov KV, Golubev GV, Terpigorev SA, Agel'tsov MV, Kuznetsov VE, Shvedov MIu: [Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease]. Urologiia; 2009 Jan-Feb;(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease].
  • The aim of our study was assessment of clinical efficacy and safety of a new alpha-adrenoblocker kamiren XL in patients with prostatic adenoma (PA) with or without acute retention of urine (ARU).
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434906.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


89. Filiadis I, Adamopoulos V, Konstandinidis E: Modification of retropubic adenomectomy: improved hemostasis and outcome. Int Urol Nephrol; 2007;39(1):169-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Our modification is based on the employment of the ligation of both the deep dorsal penile vein (DDPV) and the lateral vesicoprostatic pedicles before enucleation of adenoma in retropubic adenomectomy, for treatment of bladder outflow obstruction due to large benign prostate hyperplasia (BPH).
  • PATIENTS AND METHODS: From January 2004 till May 2005, 18 patients suffering from large BPH obstruction (mean value of adenoma 145.4 cm(3)) were operated with this modification.
  • [MeSH-minor] Blood Loss, Surgical. Hematocrit. Humans. Male. Organ Size. Prostate / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Jun;143(6):1203-4 [2342182.001]
  • [Cites] Andrologia. 1999;31 Suppl 1:77-82 [10643523.001]
  • [Cites] NCI Monogr. 1988;(7):133-7 [3173499.001]
  • [Cites] Urology. 1998 Jan;51(1):67-72 [9457291.001]
  • [Cites] Lancet. 1945 Dec 1;2(6380):693-6 [21007347.001]
  • (PMID = 17268903.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


90. Bistulfi G, Vandette E, Matsui S, Smiraglia DJ: Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol; 2010 Jan 21;8:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells.
  • We recently demonstrated that sensitivity to low folate availability is affected by the rate of polyamine biosynthesis, which is prominent in prostate cells.
  • We, therefore, hypothesized that prostate cells might be highly susceptible to genetic, epigenetic and phenotypic changes consequent to folate restriction.
  • RESULTS: We studied the consequences of long-term, mild folate depletion in a model comprised of three syngenic cell lines derived from the transgenic adenoma of the mouse prostate (TRAMP) model, recapitulating different stages of prostate cancer; benign, transformed and metastatic.
  • High-performance liquid chromatography analysis demonstrated that mild folate depletion (100 nM) sufficed to induce imbalance in both the nucleotide and AdoMet pools in all prostate cell lines.
  • These genomic changes coincided with phenotype changes in the prostate cells including increased anchorage-independent growth and reduced sensitivity to folate depletion.
  • CONCLUSIONS: This study demonstrates that prostate cells are highly susceptible to genetic and epigenetic changes consequent to mild folate depletion as compared to cells grown with supraphysiological amounts of folate (2 microM) routinely used in tissue culture.
  • These results provide a strong rationale for studying the effects of folate manipulation on the prostate in vivo, where cells might be more sensitive to changes in folate status resulting from folate supplementation or antifolate therapeutic approaches.

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1999 Jun 15;58(3):254-62 [10373323.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6872-80 [15286716.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):981-90 [15695236.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2703-9 [16251634.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90 [16243968.001]
  • [Cites] Mutat Res. 2006 Jan 29;593(1-2):80-7 [16144704.001]
  • [Cites] Gut. 2006 Oct;55(10):1387-9 [16966698.001]
  • [Cites] Genome Res. 2006 Oct;16(10):1222-30 [16954539.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10308-14 [17079450.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10349-56 [17079455.001]
  • [Cites] Exp Oncol. 2006 Sep;28(3):178-86 [17080009.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):216S-222S [17182829.001]
  • [Cites] Nat Rev Drug Discov. 2007 May;6(5):373-90 [17464296.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] Anticancer Agents Med Chem. 2007 Sep;7(5):524-42 [17896913.001]
  • [Cites] Nucleic Acids Res. 2007;35(18):e119 [17855397.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1779(1):3-16 [18078840.001]
  • [Cites] BMC Genomics. 2007;8:446 [18053125.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Nutr Biochem. 2008 May;19(5):328-35 [17681772.001]
  • [Cites] J Natl Cancer Inst. 2009 Mar 18;101(6):432-5 [19276452.001]
  • [Cites] FASEB J. 2009 Sep;23(9):2888-97 [19417083.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Nutr Cancer. 2000;37(2):245-51 [11142099.001]
  • [Cites] Genomics. 2004 Oct;84(4):647-60 [15475242.001]
  • [Cites] Biochem J. 1969 Nov;115(2):241-7 [5378381.001]
  • [Cites] Am J Hum Genet. 1979 Mar;31(2):125-35 [36752.001]
  • [Cites] Clin Chem. 1988 Nov;34(11):2357-9 [3141087.001]
  • [Cites] Cell Prolif. 1993 Jul;26(4):327-36 [8343561.001]
  • [Cites] Biochem Pharmacol. 1995 Oct 26;50(9):1433-43 [7503794.001]
  • [Cites] DNA Cell Biol. 1996 Mar;15(3):255-62 [8634154.001]
  • [Cites] Cancer Lett. 1997 May 1;115(1):31-8 [9097976.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1413-9 [11440994.001]
  • [Cites] Oncogene. 2002 May 30;21(24):3909-16 [12032829.001]
  • [Cites] Methods. 2002 Jun;27(2):144-9 [12095273.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):69-75 [12359353.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):453-8 [12355068.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2071-6 [9395204.001]
  • [Cites] Carcinogenesis. 2003 Jan;24(1):81-90 [12538352.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12(7):791-801 [12651874.001]
  • [Cites] Biochem Soc Trans. 2003 Apr;31(2):375-80 [12653642.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 1):3740S-3747S [14608108.001]
  • [Cites] Mutat Res. 2004 Apr 14;548(1-2):53-9 [15063136.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Nov;36(11):2125-30 [15313459.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • (PMID = 20092614.001).
  • [ISSN] 1741-7007
  • [Journal-full-title] BMC biology
  • [ISO-abbreviation] BMC Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / R21 CA131646; United States / NCI NIH HHS / CA / CA016056; United States / NCI NIH HHS / CA / R21 CA121216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6R795CQT4H / 5-Methylcytosine
  • [Other-IDs] NLM/ PMC2845099
  •  go-up   go-down


91. Verger-Kuhnke AB, Reuter MA, Epple W, Ungemach G, Beccaría ML: [Photoselective vaporization with the 80-watt KTP-laser (kalium-titanyl-phosphate) and low-hydraulic-pressure TURP in the treatment of BPH: our experience with 230 cases]. Arch Esp Urol; 2007 Mar;60(2):167-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La vaporizacion fotoselectiva de la HPB con el KTP-laser (kalium- titanyl-phosphat) de 80 watt y la RTU-P de baja presion hidraulica, experiencia en 230 casos.
  • The additional Resection was carried out in those patients with great adenomas or having a big middle lobe.
  • The group 1 (n: 50) just by laser treatment and small adenomas, the haemoglobin was reduced a 3.2% and nobody required a transfusion.
  • Group 2 (n: 180) with combined treatment of KTP-laser and TUR-P in great adenomas, the haemoglobin was reduced in average 13.7% after the intervention; 2 patients (1.1%) needed a transfusion.
  • CONCLUSION: Our study shows the advantages of combining both, the advantages to combine both surgical procedures to mainly obtain a better result in the ablation of the prostate adenoma in prostates of great size.
  • [MeSH-major] Laser Therapy / instrumentation. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484484.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Phosphates; 12690-20-9 / potassium titanylphosphate; D1JT611TNE / Titanium
  •  go-up   go-down


92. Endo F, Shiga Y, Minagawa S, Iwabuchi T, Fujisaki A, Yashi M, Hattori K, Muraishi O: Anteroposterior dissection HoLEP: a modification to prevent transient stress urinary incontinence. Urology; 2010 Dec;76(6):1451-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sixty-eight consecutive patients with benign prostatic hyperplasia underwent HoLEP from January to December 2008.
  • The next 37 cases (Surgery 2) underwent anteroposterior dissection HoLEP, where adenoma was dissected antegradely.
  • Surgical quality indexes (hemoglobin change, operating time, resected prostate volume) between the 2 groups were compared.
  • All patients were assessed at 2 weeks postoperatively for clinical SUI, international prostate symptom score (IPSS), quality of life (QoL), and peak flow rates (Q(max)).
  • [MeSH-major] Adenoma / surgery. Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Urinary Incontinence, Stress / prevention & control
  • [MeSH-minor] Aged. Dissection / methods. Humans. Learning Curve. Male. Middle Aged. Mucous Membrane / surgery. Organ Size. Prostate / pathology. Quality of Life. Retrospective Studies


93. Senarriaga Ruiz de la Illa N, Loizaga Iriarte A, Iriarte Soldevilla I, Lacasa Viscasillas I, Unda Urzaiz M: Pelvic hydatid disease as an example of pelvic masses of uncertain aetiology. Actas Urol Esp; 2009 Nov;33(10):1129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The other case of pelvic hydatid disease was asymptomatic, and was discovered by chance while examining a 75 year-old man for a prostatic adenoma.
  • The pathology confirmed the diagnosis in the first case and radiological findings confirmed the second.
  • Hydatid disease must be considered in the differential diagnosis of any cystic masses in the pelvic organs, especially in countries where the disease is endemic.
  • [MeSH-major] Echinococcosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096185.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


94. Uffort EE, Jensen JC: Robotic-assisted laparoscopic simple prostatectomy: an alternative minimal invasive approach for prostate adenoma. J Robot Surg; 2010 May;4(1):7-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic-assisted laparoscopic simple prostatectomy: an alternative minimal invasive approach for prostate adenoma.
  • To substantiate robotic-assisted laparoscopic simple prostatectomy (RLSP) as an alternative minimal invasive approach for the treatment of prostatic adenoma.
  • Demographic and clinical data were collected on 15 men between May 2007 and October 2009 who underwent RLSP for urinary retention secondary to benign prostate hypertrophy (BPH) and complicated by significant median lobe hypertrophy, bladder diverticula and/or stones.
  • International Prostate Symptoms Score (IPSS), postvoid residual (PVR), prostate-specific antigen (PSA) and cystoscopy, urodynamics evaluation, and operative reports were reviewed and analyzed.
  • Eleven men (73%) had urinary retention at presentation, 93.3% had significant intravesical lobe hypertrophy, 13.3% had bladder diverticula with/without stones, and mean prostate volume was 70.85 ml.
  • Mean operative time, estimated blood loss, and adenoma weight were 128.8 min, 139.3 ml, and 46.4 g, respectively.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Mar;173(3):757-60 [15711263.001]
  • [Cites] Ann Surg. 2004 Jan;239(1):14-21 [14685095.001]
  • [Cites] Urology. 2002 Oct;60(4):623-7 [12385922.001]
  • [Cites] J Endourol. 2009 Jan;23(1):129-33 [19119803.001]
  • [Cites] Urology. 2009 Apr;73(4):811-5 [19195694.001]
  • [Cites] J Urol. 2008 Feb;179(2):513-5 [18076926.001]
  • [Cites] Curr Opin Urol. 2008 Jan;18(1):41-5 [18090488.001]
  • [Cites] J Urol. 2001 Feb;165(2):459-62 [11176396.001]
  • [Cites] J Endourol. 2004 Feb;18(1):63-6; discussion 66-7 [15006057.001]
  • [Cites] Urology. 2002 Jul;60(1):39-45; discussion 45 [12100918.001]
  • [Cites] J Urol. 2006 May;175(5):1691-4 [16600732.001]
  • [Cites] J Urol. 2007 Apr;177(4):1419-22 [17382744.001]
  • (PMID = 27638565.001).
  • [ISSN] 1863-2483
  • [Journal-full-title] Journal of robotic surgery
  • [ISO-abbreviation] J Robot Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; BPH / Prostate adenoma / Prostate median lobe hypertrophy / Robotic prostatectomy / Robotic surgery / Simple prostatectomy
  •  go-up   go-down


95. Hawtrey CE, Williams RD: Historical evolution of transurethral resection at the University of Iowa: Alcock and Flocks. J Urol; 2008 Jul;180(1):55-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alcock proclaimed that transurethral resection of the prostate "...cannot be taught and can be learned only by hard, tedious experience."
  • Flocks, added basic science and anatomical knowledge to Alcock's surgical experience to create a body of work that even today provides insight into the complexities of transurethral prostatic resection.
  • MATERIALS AND METHODS: Even as Alcock studied preoperative and postoperative urethrography images to provide demonstration of the enlarged prostate, he firmly believed in the learning curve of surgical proficiency.
  • However, when Alcock and Flocks began studying autopsy material they were able to pinpoint distribution of the prostatic blood supply, and demonstrate techniques to control bleeding and perform transurethral resection in an organized fashion.
  • RESULTS: In his 1932 report to the American Urological Association Alcock detailed not only his surgical success, but also his mortality rate related to resection and prostatic obstruction and its complications.
  • In autopsy specimens with barium sulfate injections into prostatic blood vessels Flocks demonstrated that complete resection of prostate adenoma was possible and produced the desired outcome with good wound healing.
  • CONCLUSIONS: The strong collaboration between Alcock and Flocks, particularly during the 1940s, culminated in a movie presentation of the prostatic resection technique as viewed from inside the bladder antegrade toward the prostate that remains a model for surgical practice today.
  • [MeSH-major] Transurethral Resection of Prostate / history

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2008 Jul;180(1):15-6 [18485411.001]
  • (PMID = 18485410.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article; Portraits
  • [Publication-country] United States
  • [Personal-name-as-subject] Alcock NG; Flocks RH
  •  go-up   go-down


96. Vinarov AZ, Aliaev IuG, Lokshin KL: [Safety of continuous (more than 1 year) intake of Serenoa repens extract by patients with prostatic adenoma]. Urologiia; 2009 Jan-Feb;(1):84, 86-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Safety of continuous (more than 1 year) intake of Serenoa repens extract by patients with prostatic adenoma].
  • [MeSH-major] Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy. Serenoa

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432240.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts
  • [Number-of-references] 19
  •  go-up   go-down


97. Ergakov DV, Martov AG, Maksimov VA: [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit]. Urologiia; 2009 Jan-Feb;(1):24-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit].
  • We studied efficacy and safety of likoprofit pharmacotherapy in patients early after transurethral resection (TUR) of the prostate.
  • Likoprofit showed high efficacy early after TUR for prostatic adenoma in correction of irritative disorders of urination (frequent voiding, urges, painful urination with small urine portions).
  • [MeSH-major] Phytotherapy. Plant Preparations / administration & dosage. Postoperative Care. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432230.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down


98. Pavlov VN, Kazikhinurov AA, Ishemgulov RR, Mustafin AT: [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method]. Urologiia; 2008 Jan-Feb;(1):31-2, 34-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method].
  • To determine microcirculation in the wall of the urinary bladder in prostatic adenoma, we used a laser analyzer of capillary circulation LAKK-01.
  • Two groups participated in the trial: 105 males with stage II prostatic adenoma (the study group) and 25 volunteers (the control group).
  • In stage II prostatic adenoma the above microcirculation decreased to a subcritical perfusion level.
  • Significantly earlier and complete recovery of microcirculation was observed in patients who had taken cardura (Pfizer) in a dose 2 mg/day for 3 months after transurethral resection of prostatic gland.
  • Thus, 2 mg/day cardura (Pfizer) in patients with prostatic adenoma of stage II after TUR of the prostate promotes early and effective recovery of microcirculation.
  • [MeSH-major] Prostatic Hyperplasia / physiopathology. Prostatic Hyperplasia / therapy. Recovery of Function. Urinary Bladder / blood supply

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649676.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; NW1291F1W8 / Doxazosin
  •  go-up   go-down


99. Razumov SV, Egorov AA: [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma]. Urologiia; 2007 May-Jun;(3):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma].
  • A total of 58 patients with prostatic adenoma (PA) treated with prostamol Uno in combination with tamsulosin were divided into two groups: 28 patients continued the above combined therapy, 30 patients were switched to monotherapy with prostamol Uno.
  • All the patients were examined in the course of 4 visits according to standard protocol requesting information on the disease history, complaints, digital rectal examination, IPSS questionnaire, QOL, uroflowmetry with test for residual urine, transrectal ultrasonography of the prostate, blood test for PSA.
  • To the end of treatment month 9 the size of the prostate diminished by 6.7 cm3, on the average, in both groups.
  • [MeSH-major] Adrenergic alpha-1 Receptor Antagonists. Adrenergic alpha-Antagonists. Plant Extracts. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Therapy, Combination. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724829.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Plant Extracts; 0 / Prostamol-Uno; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


100. Sergienko NF, Begaev AI, Shchekochikhin AV, Vasil'chenko MI: [Choice of the surgery method in adenoma of the prostate gland]. Voen Med Zh; 2006 Jul;327(7):23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choice of the surgery method in adenoma of the prostate gland].
  • [MeSH-major] Prostatectomy / methods. Prostatic Hyperplasia / surgery
  • [MeSH-minor] Humans. Male. Transurethral Resection of Prostate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977877.001).
  • [ISSN] 0026-9050
  • [Journal-full-title] Voenno-medit︠s︡inskiĭ zhurnal
  • [ISO-abbreviation] Voen Med Zh
  • [Language] rus
  • [Publication-type] Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down






Advertisement